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Histone deacetylases (HDACs) are attractive therapeutic targets for the treatment of cancer and other
diseases. It has four classes (I-IV), among them especially class I isozyme are involved in promoting
tumor cells proliferation, angiogenesis, differentiation, invasion and metastasis and also viable targets for
cancer therapeutics. A novel series of coumarin-based benzamides was designed and synthesized as
HDAC inhibitors. The cytotoxic activity of the synthesized compounds (8a-u) was evaluated against six
human cancer cell lines including HCT116, A2780, MCF7, PC3, HL60 and A549 and a single normal cell
line (Huvec). We evaluated their inhibitory activities against pan HDAC and HDAC1 isoform. Four com-
pounds (8f, 8q, 8r and 8u) showed signiﬁcant cytotoxicity with IC50 in the range of 0.53e57.59 mM on
cancer cells and potent pan-HDAC inhibitory activity (consists of HDAC isoenzymes) (IC50 ¼ 0.80
e14.81 mM) and HDAC1 inhibitory activity (IC50 ¼ 0.47e0.87 mM and also, had no effect on Huvec
(human normal cell line) viability (IC50 > 100 mM). Among them, 8u displayed a higher potency for
HDAC1 inhibition with IC50 value of 0.47 ± 0.02 mM near equal to the reference drug Entinostat
(IC50 ¼ 0.41 ± 0.06 mM). Molecular docking studies and Molecular dynamics simulation of compound 8a
displayed possible mode of interaction between this compound and HDAC1enzyme.
© 2017 Elsevier Masson SAS. All rights reserved.1. Introduction
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served.abnormal cells, is one of the most life-threating diseases and cause
of death worldwide. Cancer causes about 550,000 deaths a year and
is second leading cause of death in the world next to heart diseases
[1,2]. The numerous drugs have been used for the cancer treatment
but have severe side effects. Consequently; increasing interest has
been devoted to the design and discovery of more effective anti-
cancer agents with promising activity and high therapeutic index in
current medicinal chemistry. Over the recent years, a great many of
important targets such as the histone deacetylase (HDAC) has been
considered for anticancer therapies. HDACs and histone acetyl
transferases (HATs) are crucial post-translational modiﬁcation and
play a pivotal role in the epigenetic regulation of gene expression
through chromatin modiﬁcation [3e6]. Histone acetyl transferase
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leads to the relaxation of chromatin and activates transcription [7].
Inversely, histone deacetylase (HDAC) catalyze the removal of
acetyl groups of the ε-amino of lysine residues on core histone and
other cellular proteins (e.g. HSP 90, tubulin), resulting in chromatin
condensation and transcriptional repression [8,9].
HDACs have an important effect on gene transcription, the cell
cycle, differentiation, apoptosis and tumourigenesis. Therefore,
HDACs have been become as prominent therapeutic target for a
broad range of human disorder such as cancer [10]. There are 18
isoforms of human HDAC, divided into four main classes based on
their homology to yeast models, subcellular localization and
enzymatic activities [11].
HDACI (HDAC 1, 2, 3 and 8), class IIa (HDAC 4, 5, 7 and 9), class IIb
(HDAC 6 and 10) and class IV (HDAC11) are zinc-dependent en-
zymes, whereas class III HDACs (sirtuins 1e7) are NADþ dependent
enzymes [12e14]. Class I HDACs are homologous to yeast Rpd3 and
are predominantly located in the nucleus (350e500 amino acids in
length) and class II HDACs have sequence homology to yeast Hda2
and shuttle between the cytoplasm and nucleus (about 1000 amino
acids in length) [15e17]. Class III are homologues of the yeast Sir2
and class IV shows the characteristics of both class I and II HDACs
[18].
Zn2þ-dependent HDACs, especially class I isozymes are involved
in promoting tumor cells proliferation, angiogenesis, differentia-
tion, invasion and metastasis and also viable targets for cancer
therapeutics [19]. Among the class I HDAC isoforms, HDAC1 has a
key role in cancer [20] and overexpressed in prostate, ovarian,
breast, colon, leukemia and pancreas cancers [21].
HDAC inhibitors (HDACIs) are categorized into four classes ac-
cording to their chemical structure in clinical studies: hydroxamic
acids (Trichostatine A (TSA)) [22], (Vorinostat (SAHA)) [23], (Pan-
obinostat (LBH-589)) [24], (Belinostat (PXD-101)) [25], benzamides
((Entinostat (MS-275)) [26], (Mocetinostat (MGCD-0103)) [27,28],
(Chidamide (CS-055)) [29], (Tacedinaline (CI-994)) [30], short-
chain fatty acids (valproic acid) [31,32] and depsipeptides (Romi-
depsin (FK-228)) [33]. Up to now, ﬁve HDACIs Vorinostat, Romi-
depsin, Belinostat, Chidamide and Panobinostat approved by FDA
for the treatment of lymphoma or myeloma [34]. The structures of
several approved and clinical HDACI are shown in Fig. 1.
Development of selective isotope HDACIs is a signiﬁcant way for
prevention of the side effects of HDACIs. Many hydroxamate
HDACIs do not exert excellent selectivity toward a speciﬁc isoform,
while 2-aminobenzamides exert some isoform selectivity such as
Entinostat and Mocetinostat are relatively unique in inhibiting
HDAC 1, 2 and 3 [35].
Despite the huge structural diversity, the HDACIs generally have
a general pharmacophore model [36]: zinc binding group (ZBG)
such as hydroxamic acid and 2-amino benzamidewhich interacting
to Zn2þ at the bottom of active site and a requirement for the
possession of HDAC inhibitory activity, a hydrophobic linker occu-
pying the narrow tunnel of HDACs and connect the ZBG and the cap
group, a polar connect unit (CU) that connecting cap group and
linker, a surface recognition group (cap), a hydrophobic and aro-
matic or heteroaromatic group, is essential for recognizing and
interacting with residues on the rim of active site of HDACs [37]. A
cap group determines the potency, stability, bioavailability and ef-
ﬁcacy of the compounds [11,38]. Coumarins (2H-1-benzopyran-2-
one or 2H-chromen-2-one), an important bicyclic heterocycle as a
part of ﬂavonoid group of plant metabolite, are a wide class of
natural and synthetic compounds that show anticancer [39], anti-
HIV [40], anti-Alzheimer [41],antimicrobial [42],antioxidant [43]
and antiviral [44] activities. Coumarin and its derivatives have
rare nephrotoxicity, hepatotoxicity, cardio toxicity, dermal toxicity
and other side effect [45].In the present study some new coumarin-based benzamides
have been designed and synthesized as HDAC inhibitors, as an
attempt to check if the replacement of the benzyl carbamatemoiety
of Entinostat or (E)-3-(pyridin-3-yl)acrylamide moiety of Chida-
mide with the coumarin carboxamide are bioisosteric. The ratio-
nale for the design of these compounds was depicted in Fig. 2. We
selected Entinostat and chidamide as the lead compounds and our
design strategy for novel HDAC inhibitors was based on the com-
mon pharmacophore model of HDACs.
The synthesized compounds were evaluated for their cytotoxic
activity against six different cancer cell lines including HCT116
(human colon cancer cells), A2780 (human ovarian cancer cells),
MCF7 (human breast cancer cells), PC3 (human prostate cancer
cells), HL60 (Human promyelocytic leukemia cells) and A549
(adenocarcinoma human alveolar basal epithelial cells) and normal
Huvec cell line (Human Umbilical Vein Endothelial Cells). We
evaluated their inhibitory activities of pan HDAC and HDAC1 iso-
form. The structure activity relationships (SAR) study performed on
the cap moiety by investigating the electronic effects of the alkoxy
or benzyloxy ringwith various substituents. Docking andmolecular
dynamics (MD) simulation were performed for further investi-
gating interaction of compounds with HDAC1.
2. Results and discussion
2.1. Chemistry
The synthetic routes to target compounds containing the
coumarin ring were illustrated in Schemes 1e3. Appropriately,
ethyl coumarin-3-carboxylates 3a-e were synthesized through the
knoevenagel condensation of salicylaldehydes 1a-e with diethyl
malonate in the presence of catalytic amount of piperidine in
ethanol. Then, O-alkylation or O-benzylation of the 7-hydroxy de-
rivative 3ewith alkyl halides or benzyl halides was done in DMF in
the presence of potassium carbonate. The ethyl esters 3a-v were
hydrolyzed with aqueous solution of sodium hydroxide to the
corresponding coumarin-3-carboxylic acids 4a-u (Scheme 1) [46].
The condensation of the carboxylic acids 4a-u with 4-(amino-
methyl) benzoic acid using N, N'-carbonyldiimidazole (CDI) and
triﬂuoroacetic acid (TFA) in dry THF at room temperature led to the
formation of compounds 6a-u (Scheme 2) [30].
Finally, compounds 6a-u were converted into imidazole inter-
mediate with CDI at 55e60 C in dry THF, then reacted in situ with
o-phenylene diamine in the presence of TFA at room temperature
to obtain the target benzamide analogs 8a-u as depicted in Scheme
3. The chemical structures of ﬁnal compounds were characterized
by 1H NMR, 13C NMR, elemental analysis, IR and MS spectroscopy.
2.2. Biological evaluation
2.2.1. In vitro anticancer activity
As depicted in Tables 1e3, the antiproliferative activity of the
target compounds (8a-u) was evaluated against seven human cell
lines including HCT116, A2780, MCF7, A549, PC3, HL60 and Huvec
by 3-(4,5-dimethylthylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assay using Entinostat as the positive control. Most of
the target compounds showed signiﬁcant anti proliferative activity
with the IC50 values in micromolar range (0.27e80 mM) over all cell
lines. Compounds 8k was the most potent compound with IC50
values of 8.48, 10.14 and 16.6 mM in MCF7, A2780 and PC3,
respectively. This compound also showed superior activity against
HCT116, A549 and HL60 cells (IC50 ¼ 0.27, 1.69 and 3.14 mM)
compared with the reference drug Entinostat (IC50 ¼ 2.03, 3.11 and
4.53 mM). Overall, the majority of the synthesized compounds were
more potent against cell proliferation in HCT116 and A2780 cell,
Fig. 1. Pharmacophore model and structures of approved and in clinical trials HDAC inhibitors.
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different mechanisms in different tumor cells. Another interesting
aspect of the results was that A549 and HL60 cell lines were sen-
sitive to all the coumarin-based derivatives (IC50 < 80 mM). Some of
the compounds showed promising antiproliferative against PC3
(8i-k; 8n-u) and MCF7 cells (8e-u) with IC50 < 80 mM.2.2.2. Cellular HDAC inhibition assay of the target compounds
Since our compounds showed more cytotoxicity effects in hu-
man colon cancer HCT116 and ovarian cancer A2780 cell lines in
comparison to other cell lines, in vitro pan-HDAC inhibitory activity
of the synthesized target compounds 8a-uwere evaluated on these
two cell lines in comparison with Entinostat as the reference drug,
the results are presented in Table 2.
Since the linker and metal binding moieties of compounds 8a-u
were identical with Entinostat; differences in cellular effects were
most likely due to the coumarin portion of the molecules as cap
group. In general benzyloxy coumarin derivatives showed stronger
HDAC inhibitory activity in comparison to alkoxy coumarin de-
rivatives; this might be because of their more lipophilicity. SAR data
showed that the position and the length of alkoxy group have key
roles in their HDAC inhibitory and cytotoxicity activities.Compounds possessing methoxy or ethoxy groups on position 7 of
coumarin (8d and 8e) showed more cytotoxicity activity than their
8-alkoxy isomers (8b and 8c). Among alkoxy coumarin derivatives,
7-propoxy derivative showed the most HDAC inhibitory and anti-
proliferative activities in most of cancer cells. Compound 8k pos-
sessing p-tolyloxy moiety was the most potent HDAC inhibitor with
IC50 value of 0.25 and 2.06 mM, in HCT116 and A2780 cell lines
respectively. This compound displayed a higher HDAC inhibitory
activity (IC50 ¼ 1.96 in HCT116) than Entinostat and IC50 ¼ 3.15 mM
in A2780 cell line). Compounds 8q and 8u also exhibited potent
HDAC inhibitory activities with IC50 values of 0.42, 0.80 mM in
HCT116 and 5.41, 4.90 mM in A2780 cancer cells, respectively.
We observed a signiﬁcant correlation between HDAC inhibition
and MTT data (r > 0.8) the same as a previous report [47]. This
correlation supported our hypothesis that HDAC inhibition medi-
ates cytotoxicity (Fig. 3.) Small differences between this assay and
cytotoxicity values may be attributed to various incubation times
used in these tests - 48 h for MTT against 18 h for HDAC inhibition
assay.
From the point of view structure activity relationship, com-
pound 8a as the simplest compound with no substitution on the
cap group displayed signiﬁcant activity against HDAC in both cell
Fig. 2. Chemical structures of known HDAC inhibitors and the structure of our designed compounds.
Scheme 1. Reagents and conditions: (a) Piperidine, EtOH, reﬂux; (b) RX, K2CO3, DMF, rt; (C) NaOH (2 N), rt and then HCl (2 N).
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stitutions at the different positions on the benzene ring of coumarin
affected the HDAC inhibition activity. Introduction of 6-bromo
substituent on coumarin ring increased inhibitory activity incompound 8g. Also, the presence of 8-methoxy and 8-ethoxy
substitutions showed higher inhibitory than parent compound
8a. 7-O-alkyl or O-benzyl derivatives could increase the activity. In
the 7-alkoxy derivatives 8d-f, 7-propoxy coumarin derivative 8f
Scheme 2. Reagents and conditions: (d) (i) CDI, THF, rt; (ii) TFA, rt.
Scheme 3. Reagents and conditions: (e) (i) CDI, THF, reﬂux; (ii) TFA, rt.
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lines. These results suggested that bulky R groups were beneﬁcial
for binding of these molecules to HDAC, which may be related to
the hydrophobic effect of the cap groups to penetrate the cell
membrane and also enlargement of cap group size facilitated
occupation of the active site and thus prevented the substrate from
entering to the catalytic center.
The O-benzyl derivative 8h with IC50 values of 2.49 and
12.82 mM in HCT116 and A2780 cell lines respectively was about
four times more potent than compound 8a.
The variety and position of substitutions on benzyl ring of
coumarin played important role in inhibitory activity. Potency in
the O-benzyl derivatives could be further improved by the intro-
duction of electron-donating or electron-driving substitutions on
the benzyl ring of the coumarin. About these substitution, a trend of
the inhibition enzymatic values is observed for
methyl>methoxy> bromo > Chloro > Fluoro>H. Compounds 8i-k
with o, m or p-methyl group on O-benzyl demonstrated signiﬁcant
HDAC inhibition with IC50 of 1.40 (o-), 1.31 (m-), 0.25 mM (p-) in
HCT116 in comparison with the values of IC50 in A2780 (20.84,
10.10 ± 0.59 and 2.06 mM respectively). Compound 8q with a 7-
bromo substituent was the most potent inhibitor between halo-
substituted compounds (8l-q). This might be due to less electro-
negativity of bromo in comparison to ﬂuoro, so the p-electron
density on the benzyl ring with bromo substituent was a little
dense. Thus, the p-p interaction between benzyl and the HDAC
active sitemight be slightly stronger. On the other, an o-substituent,
in comparison with para or meta substituent, on the benzyl
decreased the HDAC inhibition activity (8i vs 8j and 8k; 8l vs. 8m
and 8n; 8o vs 8p). These ﬁndings conﬁrmed that position of the
substitutions on the O-benzyl group had signiﬁcant effect on
enzyme activity. By comparing IC50 values of chloro derivatives, itcould be concluded that the introduction of second chloro atom
onto the benzyl ring dramatically changed the anti-HDAC activity
and 3,4-dichloro derivative 8u with 0.80 and 4.90 mM in HCT116
and A2780 was more potent than 2,3-dichloro 8s and 2,4-dichloro
8t derivatives (IC50 ¼ 7.66, 38.72 (8s) and IC50 ¼ 6.32, 27.57 (8t)).
Also, SAR data suggested that the introduction of the O-benzyl
group into C-7 position of coumarin derivatives improved the HDAC
inhibition potency than their O-alkyl group. In general, modiﬁca-
tion of the lipophilic cap group led to increase the inhibitory ac-
tivity of the target compounds against HDAC.
Direct HDAC1 inhibition assay which will be discussed below,
conﬁrmed the latter (Table 3).
ClogP is an important factor in membrane permeability and
hence antiproliferative activity. Theoretical logP (Clog P) values
(http://www.organic-chemistry.org/prog/peo/) of compounds also
were measured. These compounds had ClogP values in range of
2.43e5. (Table 2). In general there is a correlation between ClogP
values and HDAC inhibition and MTT data. Compounds with more
ClogP values, showed more activity in comparison with those with
less ClogP.2.2.3. HDAC1 inhibition assay of the target compounds
In effort for discovery of anticancer drugs, HDAC1 protein was
targeted since it is widely implicated in both transcriptional
repression and chromatin remodeling. Thus, the most potent of
compounds were selected for HDAC1 inhibition assay which
exhibited higher cytotoxic effect and HDAC inhibitory potency
(Table 2) and were not toxic to normal cells (IC50 > 100 mM).
As shown in Table 3, these compounds inhibited the deacetylase
activity of HDAC1 signiﬁcantly. Compound 8u inhibited HDAC1
with an IC50 value of 0.47 mM and showed near equal effect to
Entinostat (IC50¼ 0.41 mM). Compound 8u showedmore selectivity
Table 1
The in vitro antiproliferative activities (IC50 (mM)a) of compounds 8a-u and Entinostat against human cancer cell lines.
Compound R1 R2 R3 MCF7 A549 PC3 HL-60
8a H H H >100 80.81 ± 1.48 >100 76.64 ± 2.87
8b CH3O H H >100 76.85 ± 2.49 >100 54.19 ± 2.55
8c CH3CH2O H H >100 64.47 ± 1.00 >100 37.03 ± 1.41
8d H CH3O H >100 70.12 ± 1.71 >100 42.82 ± 1.07
8e H CH3CH2O H 77.59 ± 1.77 55.61 ± 1.98 >100 37.41 ± 1.81
8f H CH3CH2CH2O H 57.59 ± 1.19 50.51 ± 2.12 >100 45.82 ± 3.33
8g H H Br 64.81 ± 0.65 60.62 ± 1.32 80.78 ± 1.70 18.79 ± 2.70
8h H H 55.38 ± 0.24 30.76 ± 1.21 >100 18.47 ± 0.89
8i H H 17.13 ± 0.21 3.81 ± 0.13 67.14 ± 0.33 40.7 ± 0.79
8j H H 19.03 ± 0.11 3.13 ± 0.29 22.22 ± 1.25 24.97 ± 1.01
8k H H 8.48 ± 0.92 1.69 ± 0.34 16.6 ± 1.76 3.14 ± 0.63
8l H H 53.78 ± 1.71 38.26 ± 0.97 >100 71.85 ± 1.54
8m H H 52.08 ± 0.77 21.23 ± 0.683 >100 13.95 ± 0.94
8n H H 49.63 ± 1.36 13.23 ± 1.68 74.95 ± 1.90 15.57 ± 4.16
8o H H 80.63 ± 1.45 56.6 ± 0.73 68.15 ± 1.59 36.51 ± 1.84
8p H H 38.48 ± 1.98 12.26 ± 2.32 21.29 ± 1.02 17.95 ± 1.84
8q H H 23.14 ± 1.48 11 ± 0.69 48.86 ± 1.67 9.92 ± 1.43
8r H H 19.17 ± 0.88 4.51 ± 0.35 46.64 ± 1.41 12.51 ± 1.33
8s H H 13.3 ± 0.76 17.52 ± 0.14 42.98 ± 0.29 40.43 ± 1.86
8t H H 12.2 ± 0.28 6.55 ± 0.30 30.2 ± 1.04 25.42 ± 1.18
8u H H 10.41 ± 0.37 4.18 ± 0.87 22.72 ± 1.64 15.77 ± 0.75
Entinostat 4.02 ± 0.09 3.11 ± 0.04 6.36 ± 0.38 4.53 ± 0.13
a Mean ± S.D.; values are means of three independent experiments.
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8q and 8r also, exhibited signiﬁcant inhibitory activity in the
HDAC1 inhibition assay. These results demonstrated that coumarin
ring is an effective surface recognition cap for HDAC1 inhibition.
2.2.4. In vitro cytotoxicity of target compounds in normal cells
To assess toxicity of target compounds in normal cells, Huvec
cells were selected and treatedwith all of the compounds under the
same conditions following a reported procedure [48]. As shown inTable 4, lots of compounds were nontoxic (IC50 > 100 mM). In vitro
therapeutic index (IVTI) was calculated by comparing cytotoxicity
activity (IC50) of compounds against HCT116 cells, which showed
best sensitivity to test compounds, with that of compounds against
Huvec cell line. IVTI was found to be above 6. This data suggested
selective toxicity for our compounds.
Table 2
Cytotoxic Activity and HDAC Inhibition (IC50 (mM)a) of compounds 8a-u and Entinostat against Human colon cancer (HCT116) and Ovarian cancer (A2780) Cell Lines.
Compound R1 R2 R3 cytotoxicityIC50 HDAC inhibition ClogP
HCT116 A2780 HCT116 A2780
8a H H H 15.86 ± 0.72 61.87 ± 4.23 11.41 ± 0.87 54.92 ± 4.23 2.50
8b CH3O H H 9.04 ± 0.21 51.69 ± 1.35 5.17 ± 0.21 40.09 ± 1.35 2.43
8c CH3CH2O H H 8.73 ± 0.35 45.67 ± 1.49 2.04 ± 0.49 32.86 ± 1.49 2.43
8d H CH3O H 8.16 ± 0.44 35.87 ± 1.31 3.08 ± 0.25 21.62 ± 1.31 2.43
8e H CH3CH2O H 5.32 ± 0.25 29.95 ± 0.60 2.31 ± 0.44 17.04 ± 1.75 2.84
8f H CH3CH2CH2O H 3.34 ± 0.11 20.87 ± 2.38 1.09 ± 0.11 14.81 ± 2.38 3.29
8g H H Br 7.70 ± 0.36 52.07 ± 2.40 6.64 ± 0.36 27.52 ± 2.21 3.23
8h H H 2.94 ± 0.18 19.51 ± 1.02 2.49 ± 0.18 12.82 ± 1.02 3.85
8i H H 1.65 ± 0.22 40.36 ± 1.49 1.40 ± 0.22 20.84 ± 1.49 4.20
8j H H 1.83 ± 0.51 19.13 ± 1.75 1.31 ± 0.33 10.10 ± 0.59 4.20
8k H H 0.27 ± 0.03 10.14 ± 1.75 0.25 ± 0.02 2.06 ± 0.10 4.20
8l H H 10.17 ± 1.15 42.90 ± 0.78 9.32 ± 0.50 17.33 ± 1.90 3.95
8m H H 5.30 ± 0.54 30.83 ± 1.12 3.73 ± 0.54 15.77 ± 1.12 3.95
8n H H 3.50 ± 0.56 15.37 ± 1.90 2.46 ± 0.47 9.72 ± 1.90 3.95
8o H H 6.55 ± 0.78 50.33 ± 1.45 4.76 ± 0.51 10.09 ± 1.45 4.46
8p H H 2.35 ± 0.32 31.22 ± 1.90 1.77 ± 0.27 6.04 ± 0.78 4.46
8q H H 0.53 ± 0.47 2.207 ± 0.91 0.42 ± 0.03 5.41 ± 1.75 4.58
8r H H 1.04 ± 0.27 27.53 ± 2.21 1.00 ± 0.12 6.52 ± 0.40 3.78
8s H H 7.66 ± 0.14 38.72 ± 1.50 6.14 ± 0.78 29.33 ± 1.50 5.06
8t H H 6.32 ± 0.57 27.57 ± 1.47 4.26 ± 0.32 23.86 ± 1.47 5.06
8u H H 1.76 ± 0.30 7.77 ± 0.31 0.80 ± 0.01 4.90 ± 0.31 5.06
Entinostat 2.03 ± 0.26 5.89 ± 0.21 1.96 ± 0.13 3.15 ± 0.21 4.52
a Mean ± S.D.; values are means of three independent experiments.
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In order to investigate the binding mode of the target com-
pounds in the catalytic site of the HDAC1 (PDB ID: 4BKX), docking
studies was carried out using Auto Dock 4.2. The best pose of each
ligand in terms of free energy of binding was extracted from the
100 generated top poses the binding mode of compounds 8a-g andthe most potent compounds 8f, 8q, 8r, 8u and Entinostat are shown
in Fig. 4. Coumarins derivatives docked well to HDAC1 and bound
similar to Entinostat.
The docking pose of 8a, the simplest coumarin in the series, in
complex with HDAC1 was shown in Figs. 5 and 6. HDAC1 is a zinc-
dependent enzyme and its active site consisted of a long, narrow
tunnel leading to a cavity that contains the catalytic Zn ion.
Table 3
HDAC1 inhibition activity (IC50 (mM)a) and isoform selectivity of 8f, 8q, 8r and 8u.
Compound HDAC (HCT116) HDAC (A2780) HDAC1 HDAC1/HDAC (HCT116)
Isoform selectivity
HDAC1/HDAC (A2780)
Isoform selectivity
8f 1.09 ± 0.11 14.81 ± 2.38 0.87 ± 0.05 0.80 0.06
8q 0.42 ± 0.03 2.06 ± 0.21 0.50 ± 0.15 1.19 0.24
8r 0.80 ± 0.06 6.52 ± 0.40 0.71 ± 0.05 0.89 0.11
8u 1.00 ± 0.10 4.9 ± 0.31 0.47 ± 0.02 0.47 0.10
Entinostat 1.96 ± 0.13 3.15 ± 0.21 0.41 ± 0.06 0.21 0.13
a Mean ± S.D.; values are means of three independent experiments.
Fig. 3. Correlation between HDAC inhibition (HDAC inhibition assay, pIC50) and cytotoxic activity (MTT assay, pIC50) of all test compounds and Entinostat.
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as well as the carbonyl and aniline of benzamide of compound 8a.
The protons of aniline formed hydrogen bonds with His140 and His
141 while NH of amide could also form a hydrogen binding inter-
action with Gly 149. The carbonyl oxygen of the benzamide group
made hydrogen binding interaction with the phenolic hydroxyl
group of Tyr303. Nevertheless, the aryl linker region of compound
8a was located in the lipophilic tube including Leu271, Phe 205,
Phe150, Met39 and Glu98. There was also p-p stacking interaction
with benzene group of Phe150 which improved the binding afﬁnity
of compound 8a to HDAC1.
Linear regression analysis of calculated binding afﬁnities, Ki
versus experimental cytotoxicity values, IC50 (Fig. 7.) showed that
there was maximum correlation in case of HCT116 cells (r ¼ 0.88;
r2 ¼ 0.78) and minimum correlation in PC3 cells (r ¼ 0.58;
r2 ¼ 0.35).2.4. Molecular dynamic simulation
Molecular dynamic simulation has been done to elucidate
behavior of HDAC1 enzyme upon binding to inhibitor and stability
and interaction of structure throughout simulation. The dynamic
stability of secondary structure elements and conformational
changes in ligand-bond protein were compared with apo-form of
HDAC1 by root-mean-square derivations (RMSD) and root mean
square ﬂuctuation (RMSF) plots for 70 ns simulations.
RMSD is a measure of the stability of the structures. Fig. 8
showed that the RMSD of backbone (Ca, C, and N) of apo-form
and ligand-bond protein 8a reached stability after about 20ns of
simulation. The average RMSD value of apo-form was 1.88 ± 0.133
A , whereas the ligand-bond protein was also converged very close
to apo-formwith average RMSD value of 2.27 ± 0.15 A . The average
RMSD value of ligand 8a was 0.04 ± 0.024 A (Fig. S1) and ligand
was stable during simulation. In RMSD of ligand-bond protein, the
change was slightly larger than apo-form. It seemed that binding of
ligandwith protein increased the conformation ﬂexibility of HDAC1enzyme.
A root mean square ﬂuctuation (RMSF) is an indicator of the
macromolecular ﬂexibility and indicates local changes in the pro-
tein structure [49]. The RMSF plots of apo-form and ligand-bond
protein was illustrated in Fig. 9 and Fig. S2 in the Supplementary
data. The protein structures of the two systems had similar RMSF
distribution and same trends of dynamic features. The average
RMSF of ligand-bond protein and apo-form were 0.73 ± 0.456 and
0.85 ± 0.533 A , respectively. The relatively lower RMSF values of
ligand-bond protein were found for residues located in the binding
site (Asp176, His 178, Gly149, Asp264, His 140, and His 141and
Tyr303). This could be explained by the relatively stronger binding
of ligand with these residues that led to their less ﬂexibility. The
high ﬂuctuating residues indicated that they were far from the
active site or located in the loops (regionsmarked in bracket lines in
Fig. 9) or terminals of protein.
To analyze in a more quantitative way, contribution of different
residues at the active site (His140,His141, Gly149, Asp176, His178,
Asp264 and Tyr303) in electrostatic, VdW and total interaction
energy between ligand and HDAC1 was calculated (Fig. S3 in Sup-
plementary data).
Radius of gyration (Rg) is a parameter that describes the equi-
librium conformation of a total system and is an indicator of the
protein structure compactness. As shown in Fig. 10, Rg values of the
apo-form and ligand-bond protein 8a were 20.53 ± 0.095 and
20.48 ± 0.085 A

(mean ± SD), respectively. The graphs showed that
radius of gyration of apo-form was increased for the ﬁrst 20 ns of
simulation and then remained constant. It was observed that Rg of
the ligand-bond protein was constant and larger than apo-form.
Hydrogen bonds play an essential role in stability ligand-protein
complex. This stability of the hydrogen-bond network formed by
the ligand in the protein active site analyzed in Fig. 11. The results
showed that ligand formed three to four hydrogen bonds with
protein. The benzamide group of ligand made three hydrogen
bonds with His 140, His 141 and Gly 149 and also, the benzamide
carbonyl of ligand could form strong bondwith hydroxyl of Tyr 303.
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HDAC. The mean of intramolecular hydrogen bonds of the protein
were 80 ± 7.19. These hydrogen bonds stabilized the secondary
structure of HDAC1 (Fig. S4 in Supplementary data).
The percentage of protein secondary structures was investigated
and it was found to be unchanged during simulation (Fig. S5 and S6
in Supplementary data).
Another simple way to measure the stability of system is po-
tential energy. The ligand bond protein potential energy was found
to be 33259.5 ± 13.35 kcal/mol indicating the stability of the
system (Fig. S7 in Supplementary data).
The average distance between coordinated Zn2þ ion with active
site residues (Asp176, His178 and Asp264) was in the range
2.02 ± 0.05 to 3.90 ± 0.19 A

(Fig. S8 in Supplementary data). In
addition, the distance between carbonyl and amino groups of
ligand with Zn2þ ion was in the range of 2.09 ± 0.07 to 2.21 ± 0.08
A

.These results improved the expected penta-coordination com-
plex between HDAC1 residues and ligand with zinc ion at the
enzyme active site. To discover the system condition during
simulation, ligand bond protein structure was extracted from tra-
jectories for each 5 ns (Fig. S9 in Supplementary data). These
snapshots proved ﬁxed orientation of ligand at the active site of the
HDAC1 throughout simulation.
The 2D representation of the interaction between compound 8a
after 70ns simulation by LigPlot [50] has been depicted in Fig. 12.2.5. ADME analysis
The ADME parameters of coumarin compounds and Entinostat
as drug reference were measured using QikProp software (Table 5).
All of the coumarins showed good partition coefﬁcient (QplogPo/w)
in permeable range of 2.90e5.62. The Caco-2 cell permeability
(QPPCaco) was in the permissible range of 126.98e128.52. Also, the
percentage human oral absorption for the compounds ranged from
70 to 86%. All of the parameters were within the acceptable range
deﬁned for human use and these compounds may exhibit signiﬁ-
cant pharmacokinetic and drug likeliness properties.3. Conclusion
A new class of coumarin-based benzamides as HDAC inhibitors
was designed, synthesized and evaluated for their in vitro anti-
proliferative activities byMTTassay against human cancer (HCT116,
A2780, MCF7, PC3, HL60 and A549) and normal (Huvec) cell line as
well as for pan HDAC and HDAC1 isoform inhibitory activities. Most
of compounds exhibited signiﬁcant cytotoxicity and potent HDAC
inhibition activity. Four compounds (8f, 8q, 8r and 8u) showed
superior cytotoxicity activities (IC50 ¼ 0.53e57.59 mM) on cancer
cells and higher enzymatic pan HDAC (IC50 ¼ 0.80e14.81 mM) and
HDAC1 (IC50 ¼ 0.47e0.87 mM) inhibitory activities and also, had no
effect on Huvec viability (IC50 > 100 mM). Among them, 8u dis-
played a higher potency for HDAC1 inhibition with IC50 value of
0.47 ± 0.02 mM comparable with Entinostat (IC50¼ 0.41 ± 0.06 mM).
Molecular docking studies of coumarin derivatives showed that
they could bind tightly to the active site of HDAC1. Molecular dy-
namics simulation showed interaction mode of lead compound 8a
with HDAC1 including zinc ion coordination, strong hydrophobic
interactions and formation of hydrogen bond with lead compound
8a.These ﬁndings suggested that coumarin derivatives could be
promising lead compounds for further development of anticancer
agents through HDACs inhibition.4. Experiment section
4.1. Chemistry
All reagents and solvents were purchased fromMerck& Co., Inc.
(Darmatadt, Germany) and Acros Organics (Thermoﬁsher, Belgium)
and used without further puriﬁcation. Entinostat and vorinostat
were purchased from EuroAsia Chemicals@ (www.euroasiarnd.
com). The progress of all reactions was monitored by thin-layer
chromatography with 0.25 mm Silica gel plates (60 GF-254-
Merck & Co (Darmatadt, Germany)) and visualized using UV light
and iodine vapor. Melting points were measured with an electro-
thermal melting point apparatus (Stafford, UK) and were uncor-
rected. Infrared spectra were recorded on a Perkin Elmer Model
1420 spectrometer (KBr disks, Massachusetts, USA).1H NMR and
13CNMR spectra were determined at 300 MHz and 75 MHz,
respectively (DMSO-d6, TMS) on a Bruker FT-300 MHz instrument
(Karlsruhe, Germany). The chemical shifts (d) and coupling con-
stants (J) are expressed in parts per million and Hertz, respectively.
Spin multiples are given as s (singlet), d (doublet), t (triplet), q
(quartet), s (sextet), m (multiplet). Mass spectra were obtained
from a 6410 Agilent LC-MS triple quadrupole mass spectrometer
(LC-MS, Santa Clara, USA) with an electrospray ionization (ESI)
interface. Elemental analyses were performed on a Cos-Tec model
EAS 4010 instrument (Cernusco, Italy) and the results are within
±0.4% of the theoretical values. Cell lines, including HCT116, A2780,
MCF7, A549, HL60, PC3 and Huvec purchased from Pasteur Institute
Cell Bank of IRAN (Tehran, IRAN).
4.2. General procedure for the synthesis of ethyl 2-oxo-2H-
chromene-3-carboxylates (3a-u)
Diethyl malonate (2.11mmol) and piperidine (2 mL) were added
to a solution of the appropriate salicylaldehyde derivatives (1a-e)
(10 mmol) in ethanol (20 mL) and the resulting mixture was
reﬂuxed for 14e15 h until the disappearance of the starting ma-
terials (monitored by TLC). After cooling, the crude product was
ﬁltrated, washed with cold ethanol and recrystallized from ethanol.
4.3. General procedure for the synthesis of ethyl 7-alkyl or aryl-2-
oxo-2H-chromene-3-carboxylates (3f-v)
Potassium Carbonate (6 mmol) was added to ethyl 7-hydroxy-2-
oxo-2H-chromene-3-carboxylate (3e, 5 mmol) in DMF (20 mL) and
the mixture was stirred at rt for several minutes, then appropriate
alkyl halide or benzyl halide derivatives (14 mmol) were added
dropwise to the mixture and stirred for 10e12 h. Upon completion,
water is added to the mixture and the produced precipitate was
ﬁltrated, washed with water and used in the next step without
further puriﬁcation.
4.4. General procedure for the synthesis of 2-oxo-2H-chromene-3-
carboxylic acids (4a-u)
Esters (3a-v) were dissolved in aqueous sodium hydroxide (2 N,
20 mL) and were stirred at rt for 5e7 h. After cooling, solution was
acidiﬁed with hydrochloric acid (2 N) until a white precipitate
formed. The white solid was ﬁltrated, washed with water and dried
to yield acids (4a-u).
4.5. General procedure for the synthesis of 4-((2-oxo-2H-
chromene-3-carboxamido) methyl) benzoic acid derivatives (6a-u)
the corresponding 2-oxo-2H-chromene-3-carboxylic acids (3a-
v, 5 mmol) was added to a suspension of 1, 1-carbonyldimidazole
Table 4
The in vitro cell proliferation activities (IC50 (mM)a) of compounds 8a-u and Enti-
nostat against human normal cell line.
Compound Huvec In vitro therapeutic index
(Huvec IC50/HCT116 IC50)
8a >100 >6.30
8b >100 >11.06
8c >100 >11.45
8d >100 >12.25
8e >100 >18.80
8f >100 >29.94
8g 76.287 ± 2.33 9.90
8h 50.51 ± 1.00 17.18
8i 49.553 ± 4.77 30.03
8j 20.833 ± 3.91 11.38
8k 40.8 ± 5.73 >50
8l 61.833 ± 2.43 6.07
8m 57.68 ± 1.02 10.88
8n 75.58 ± 3.01 21.59
8o >100 >15.26
8p >100 >42.55
8q >100 >50
8r >100 >50
8s >100 >13.05
8t >100 >15.82
8u >100 >56.8
Entinostat >100 >49.26
a Mean ± S.D.; values are means of three independent experiments.
Fig. 4. The best pose of the compounds obtained from docking study in the active site
of HDAC1. A; (compounds 8a-8g). B; (compounds 8f, 8q, 8r, 8u and Entinostat (in
pink)). The important residues of binding site (Asp264, His178, and Asp176) and zinc
ion were shown. (For interpretation of the references to colour in this ﬁgure legend,
the reader is referred to the web version of this article.)
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was stirred for 2 h at rt. Then 4-(aminomethyl) benzoic acid (5,
25 mmol) and triﬂuoroacetic acid (TFA, 1.2 mL) were added and
stirred for additional 10 h at rt. The mixture was evaporated to
remove THF and extracted with EtOAc, dried over anhydrous
Na2SO4 and concentrated under reduced pressure. Further puriﬁ-
cation was done with preparative thin layer chromatography for
some compounds (6p and 6q). Due to very low solubility of com-
pounds 6g, 6i and 6m, we could not report 13C NMR data for these
compounds.
4.5.1. 4-((2-oxo-2H-chromene-3-carboxamido) methyl) benzoic
acid (6a)
White solid; yield:78%; mp: 261e263 C; Rf ¼ 0.56 (petroleum
ether: ethyl acetate ¼ 3:1); IR (KBr): nmax (cm1) 3312 (NH), 1709
1602 (CO); 1H NMR (300 MHz, DMSO-d6) d 4.63 (d, 2H,
J ¼ 6.0 Hz,CH2), 7.44e7.54 (m, 4H, Ar-H), 7.77 (t, 1H, J ¼ 6.0 Hz, Ar-
H), 7.92 (d, 2H, J¼ 9.0 Hz, Ar-H), 7.99 (d,1H, J¼ 9.0 Hz, Ar-H), 8.90 (s,
1H, CH), 9.23 (t, 1H, J ¼ 6.0 Hz, NH); 13C NMR (75 MHz, DMSO-d6)
d 43.04, 116.62, 118.94, 119.57, 125.62, 127.78, 129.88, 130.06, 130.75,
134.61, 144.56, 148.08, 154.40, 160.73, 161.96, 167.60; Anal. calcd. for
C18H13NO5: C, 66.87; H, 4.05; N, 4.33; found: C 66.80, H 4.09, N 4.24.
4.5.2. 4-((8-methoxy-2-oxo-2H-chromene-3-carboxamido)
methyl) benzoic acid (6b)
White solid; yield: 73%; mp: 238e240 C; Rf ¼ 0.49 (petroleum
ether: ethyl acetate ¼ 3:1); IR (KBr): nmax (cm1) 3347 (NH), 1712
&1606 (CO); 1H NMR (300MHz, DMSO-d6) d 3.95 (s,1H, OCH3), 4.62
(d, 2H, J ¼ 6.0 Hz, CH2), 7.35e7.54 (m, 5H, Ar-H),7.91 (d, 1H,
J ¼ 8.1 Hz, Ar-H), 8.85 (s, 1H, CH), 9.24 (t, 1H, J ¼ 5.7 Hz, NH); 13C
NMR (75 MHz, DMSO-d6) d 43.05, 56.65, 116.53, 119.46, 119.57,
121.62, 125.54, 127.81, 129.36, 137.81, 143.69, 144.56, 146.73, 148.30,160.44, 161.83, 167.60; Anal. calcd. for C19H15NO6: C, 64.59; H, 4.28;
N, 3.96; found: C 64.66, H 4.20, N 4.05.
4.5.3. 4-((8-ethoxy-2-oxo-2H-chromene-3-carboxamido) methyl)
benzoic acid (6c)
Pale yellow solid; yield: 79%; mp: 246e248 C; Rf ¼ 0.43 (pe-
troleum ether: ethyl acetate ¼ 3:1); IR (KBr): nmax (cm1) 3335
(NH), 1707 and 1653 (CO); 1H NMR (300 MHz, DMSO-d6) d 1.42 (t,
3H, J ¼ 6.9Hz, CH3), 4.20 (q, 2H, J ¼ 6.9Hz,OCH2), 4.62 (d, 2H,
J ¼ 6.0Hz, CH2), 7.34 (d, 1H, J ¼ 7.5Hz, Ar-H), 7.42e7.48 (m, 3H, Ar-
H), 7.52 (dd, 1H, J1 ¼ 7.5Hz, J2 ¼ 1.2Hz, Ar-H), 7.92 (d, 2H, J ¼ 8.1Hz,
Ar-H), 8.86 (s, 1H, CH), 9.23 (t, 1H, J¼ 6.0Hz, NH); 13C NMR (75MHz,
DMSO-d6) d 15.04, 43.03, 65.02, 117.43, 119.56, 119.59, 121.62,
125.56, 127.82, 129.89, 137.82, 143.79, 144.63, 145.98, 148.37, 160.53,
161.96,167.66; Anal. calcd. for C20H17NO6: C, 65.39; H, 4.66; N, 3.81;
found: C 65.30, H 4.73, N 3.75.
4.5.4. 4-((7-methoxy-2-oxo-2H-chromene-3-carboxamido)
methyl) benzoic acid (6d)
Light brown; yield: 89%; mp: 242e244 C; Rf ¼ 0.46 (petroleum
Fig. 5. 3D representation of docked ligand 8a into the tunnel-like binding site of
HDAC1.
Fig. 6. The 2D representation of the interaction between compound 8a in the crystal structure of HDAC1.
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1659 &1614 (CO); 1H NMR (300 MHz, DMSO-d6) d 3.89 (s, 3H,
OCH3), 4.62 (d, 2H, J ¼ 6.0Hz, CH2), 7.02 (dd, 1H, J1 ¼ 8.7Hz,
J2¼ 2.4Hz, Ar-H), 7.09 (d, 1H, J¼ 2.1Hz, Ar_H), 7.45 (d, 2H, J¼ 8.1Hz,
Ar-H), 7.90 (m, 3H, Ar-H), 8.83 (s, 1H, CH), 9.17 (t, 1H, J¼ 6.0Hz, NH),
12.91 (brs, 1H, OH); 13C NMR (75 MHz, DMSO-d6) d 42.98, 56.67,
100.69, 112.54, 114.05, 115.16, 127.77, 129.84, 129.90, 131.99, 144.77,148.47, 156.64, 161.24, 162.20, 164.90, 167.65; Anal. calcd. for
C19H15NO6: C, 64.59; H, 4.28; N, 3.96; found: C 64.48, H 4.34, N 3.89.
4.5.5. 4-((7-ethoxy-2-oxo-2H-chromene-3-carboxamido) methyl)
benzoic acid (6e)
Pale yellow solid; yield: 85%; mp: 245e247 C; Rf ¼ 0.59 (pe-
troleum ether: ethyl acetate ¼ 3:1)
IR (KBr): nmax (cm1) 3339 (NH), 1718, 1654 and 1613 (CO); 1H
NMR (300 MHz, DMSO-d6) d 1.38 (t, 3H, J ¼ 6.6Hz, CH3), 4.18 (q, 2H,
J ¼ 6.9Hz, OCH2), 4.67 (d, 2H, J ¼ 6.6Hz, CH2), 7.05 (m, 2H, Ar-H),
7.50 (d, 2H, J ¼ 7.8Hz, Ar-H), 7.92 (d, 2H, J ¼ 6.9Hz, Ar-H), 8.10 (d,
1H, J ¼ 7.8Hz, Ar-H), 8.86 (s, 1H, CH), 9.20 (t, 1H, J ¼ 7.8Hz, NH),
12.90 (brs, 1H, OH); 13C NMR (75 MHz, DMSO-d6) d 14.82, 42.84,
64.89, 101.49, 112.49, 114.38, 115.14, 127.79, 129.70, 129.90, 131.03,
144.86, 148.54, 156.71, 161.28, 162.17, 164.22, 167.54; Anal. calcd. for
C20H17NO6: C, 65.39; H, 4.66; N, 3.81; found: C 65.29, H 4.75, N 3.74.
4.5.6. 4-((2-oxo-7-propoxy-2H-chromene-3-carboxamido) methyl)
benzoic acid (6f)
Yellow solid; Yield: 82%; mp: 259e261 C; Rf ¼ 0.55 (petroleum
ether: ethyl acetate ¼ 3:1)IR (KBr): nmax (cm1) 3333 (NH), 1701, 1659 and 1618 (CO); 1H
NMR (300MHz, DMSO-d6) d 1.00 (t, 3H, J¼ 7.2Hz, CH3), 1.77 (se, 2H,
J ¼ 6.9Hz, CH2), 4.10 (t, 2H, J ¼ 6.6Hz, OCH2), 4.62 (d, 1H, J ¼ 6.0Hz,
CH2), 7.04 (dd,1H, J1¼8.7Hz, J2¼ 2.4Hz, Ar-H), 7.11 (d,1H, J¼ 2.1Hz,
Ar-H), 7.45 (d, 2H, J ¼ 8.4Hz, Ar-H), 7.89e7.93 (m, 3H, Ar-H), 8.86 (s,
1H, CH), 9.19 (t, 1H, J ¼ 6.0Hz, NH); 13C NMR (75 MHz, DMSO-d6)
d 10.75, 22.23, 42.95, 70.55, 110.13, 112.49, 114.40, 115.12, 127.78,
Fig. 7. Linear regression analysis of predicted HDAC1 binding afﬁnities (Ki) versus experimental cytotoxic effects (IC50).
Fig. 8. RMSD between HDAC1 with ligand and without ligand.
Fig. 9. Per residue RMSF of HDAC1 with ligand and without ligand during 70 ns
simulation. Residues with RMSF greater than 2A

were marked in braket lines.
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Fig. 10. Rg of HDAC1 with ligand and without ligand.
Fig. 11. Number of hydrogen bonds between HDAC1 and ligand in time scale.
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167.56; Anal. calcd. for C21H19NO6: C, 66.13; H, 5.02; N, 3.67; found:
C 65.20, H 4.93, N 3.73.
4.5.7. 4-((6-bromo-2-oxo-2H-chromene-3-carboxamido) methyl)
benzoic acid (6g)
White solid; yield: 86%; mp: 295e297 C; Rf ¼ 0.46 (petroleum
ether: ethyl acetate ¼ 3:1); IR (KBr): nmax (cm1) 3349 (NH), 1713,
1653 and 1611 (CO); 1H NMR (300 MHz, DMSO-d6) d 4.62 (d, 2H,
CH2), 7.44e7.51 (m, 3H, Ar-H), 7.88e7.93 (m, 3H, Ar-H), 8.26 (d, 1H,
J ¼ 2.1Hz, Ar-H), 8.84 (s, 1H, CH), 9.21 (t, 1H, J ¼ 6.0Hz, NH); Anal.
calcd. for C18H12BrNO5: C, 53.75; H, 3.01; N, 3.48; found: C 53.68, H
3.10, N 3.37.
4.5.8. 4-((2-oxo-7-phenoxy-2H-chromene-3-carboxamido) methyl)
benzoic acid (6h)
Yellow solid; yield:85%; mp: 245e247 C; Rf ¼ 0.34 (petroleum
ether: ethyl acetate ¼ 3:1); IR (KBr): nmax (cm1) 3340 (NH), 1705,
1658 and 1613 (CO); 1H NMR (300 MHz, DMSO-d6) d 4.61 (d, 2H,
J¼ 6.0Hz, CH2), 5.28 (s, 2H, CH2), 7.12 (dd,1H, J1¼8.7Hz, J2¼ 2.1 Hz,
Ar-H), 7.21 (d, 1H, J ¼ 2.1Hz, Ar-H), 7.35 (m, 7H, Ar-H), 7.91 (m, 3H,
Ar-H), 8.85(s. 1H, CH1), 9.18 (t, 1H, NH), 12.89 (s, 1H, OH); 13C NMR
(75 MHz, DMSO-d6) d 42.96, 70.68, 101.66, 112.77, 114.65, 115.46,
127.07, 127.79, 128.51, 128.72, 129.05, 129.90, 132.12, 136.44, 144.83,
148.45, 156.58, 161.22, 162.25, 163.91, 167.59; Anal. calcd. for
C25H19NO6: C, 69.92; H, 4.46; N, 3.26; found: C 69.90, H 4.39, N 3.32.
4.5.9. 4-((2-oxo-7-(o-tolyloxy)-2H-chromene-3-carboxamido)
methyl) benzoic (6i)
Pink solid; yield: 83%; mp: 229e231 C; Rf ¼ 0.45 (petroleum
ether: ethyl acetate ¼ 3:1); IR (KBr): nmax (cm1) 3342 (NH), 1705,1657 &1610 (CO); 1H NMR (300 MHz, DMSO-d6) d 2.33 (s, 3H, CH3),
4.61 (d, 2H, J ¼ 5.7Hz, CH2), 5.24 (s, 2H, OCH2), 7.10 (dd, 1H,
J1 ¼ 8.7Hz, J2 ¼ 2.1Hz, CH2), 7.19e7.25 (m, 4H, Ar-H), 7.43e7.47 (m,
3H, Ar-H) 7.89e7.94 (m, 3H, Ar-H), 8.85 (s, 1H, CH), 9.18 (t, 1H,
J ¼ 6.0Hz, NH), 12.89 (s, 1H, OH); Anal. calcd. for C26H21NO6: C,
70.42; H, 4.77; N, 3.16; found: C 70.50, H 4.73, N 3.25.
4.5.10. 4-((2-oxo-7-(m-tolyloxy)-2H-chromene-3-carboxamido)
methyl)benzoic acid (6j)
Pale yellow solid; Yield:85%; mp: 228e230 C; Rf ¼ 0.30 (pe-
troleum ether: ethyl acetate ¼ 3:1); IR (KBr): nmax (cm1) 3331
(NH), 1703, 1655 & 1618 (CO); 1H NMR (300 MHz, DMSO-d6) d 2.24
(s, 3H, CH3), 4.62 (d, 2H, J ¼ 6.0Hz,CH2), 5.23 (s, 2H, OCH2),
7.07e7.34 (m,6H, Ar-H), 7.44 (d, 2H, J ¼ 8.1Hz, Ar-H), 7.90e7.94 (m,
3H, Ar-H), 8.86 (s, 1H, CH), 9.18 (t, 1H, J ¼ 6.0Hz, NH), 12.93 (s, 1H,
OH); 13C NMR (400 MHz, DMSO-d6) d 21.45, 42.97, 70.73, 101.61,
112.75, 114.63, 115.42, 125.60, 127.78, 128.94, 129.05, 129.33,
129.82,132.10, 136.34,138.24, 144.81, 148.46, 156.58, 161.23, 162.23,
163.94, 167.63; Anal. calcd. for C26H21NO6: C, 70.42; H, 4.77; N, 3.16;
found: C 70.52, H 4.70, N 3.23.
4.5.11. 4-((2-oxo-7-(p-tolyloxy)-2H-chromene-3-carboxamido)
methyl)benzoic acid (6k)
Pale yellow solid; Yield:89%; mp: 264e266 C; Rf ¼ 0.35 (pe-
troleum ether: ethyl acetate ¼ 3:1)
IR (KBr): nmax (cm1) 3321 (NH), 1700, 1651&1611(CO); 1H NMR
(300 MHz, DMSO-d6) d 2.36 (s, 3H, CH3), 4.65 (d, 2H, J ¼ 6.0Hz,
CH2),5.27 (s, 1H, OCH2) 7.14 (dd, 1H, J1 ¼ 8.7Hz, J2 ¼ 2.4Hz, Ar-H),
7.24e7.28 (m, 3H, Ar-H), 7.41 (d, 2H, J ¼ 8.1Hz, Ar-H), 7.48 (d, 2H,
J ¼ 8.1Hz, Ar-H), 7.94e7.97 (m, 3H, Ar-H), 8.90 (s, 1H, CH), 9.22 (t,
1H, J ¼ 6.0Hz, NH), 12.97 (s, 1H, OH); 13C NMR (75 MHz, DMSO-d6)
d 21.26, 42.97, 70.60, 101.64, 112.71, 114.66, 115.39, 127.78, 128.61,
129.36, 129.57, 129.89, 132.08, 133.39,138.02, 144.80, 148.46, 156.58,
161.23, 162.23, 163.94, 167.64; Anal. calcd. for C26H21NO6: C, 70.42;
H, 4.77; N, 3.16; found: C 70.35, H 4.83, N 3.18.
4.5.12. 4-((7-(2-ﬂuorophenoxy)-2-oxo-2H-chromene-3-
carboxamido) methyl) benzoic acid (6l)
Yellow solid; yield: 92%; mp: 238e240 C; Rf ¼ 0.38 (petroleum
ether: ethyl acetate ¼ 3:1); IR (KBr): nmax (cm1) 3340 (NH), 1713,
1695 and 1616 (CO); 1H NMR (300 MHz, DMSO-d6) d 4.61 (d, 2H,
J ¼ 6.0 Hz,CH2), 5.31 (s, 2H, OCH2), 7.13 (dd, 1H, J1 ¼ 8.7Hz,
J2 ¼ 2.4Hz, Ar-H), 7.25e7.33 (m, 3H, Ar-H), 7.45 (m, 3H, Ar-H), 7.62
(t,1H, J¼ 7.2Hz, Ar-H), 7.90e7.96 (m, 3H, Ar-H), 8.86 (s,1H, CH), 9.19
(t, 1H, J ¼ 6.0Hz, NH), 12.93 (1H, OH); 13C NMR (75 MHz, DMSO-d6)
d 42.98, 65.07, 101.55, 112.90, 114.44, 115.55, 115.86, 123.33, 125.14,
127.77, 129.90, 131.45, 131.56, 131.61, 132.14, 144.77, 148.41, 156.55,
159.39, 161.21, 162.21, 163.67, 167.66; Anal. calcd. for C25H18FNO6: C,
67.11; H, 4.06; N, 3.13; found: C 67.20, H 4.12, N 3.04.
4.5.13. 4-((7-(3-ﬂuorophenoxy)-2-oxo-2H-chromene-3-
carboxamido) methyl) benzoic acid (6m)
Pale yellow solid; yield: 80%; mp: 259e261 C; Rf ¼ 0.39 (pe-
troleum ether: ethyl acetate ¼ 3:1); IR (KBr): nmax (cm1) 3338
(NH),1711,1657 and 1614 (CO); 1H NMR (300MHz, DMSO-d6) d 4.61
(d, 2H, J ¼ 6.0 Hz,CH2), 5.30 (s, 2H, OCH2), 7.13e7.23 (m, 3H, Ar-H),
7.33 (d, 2H, J ¼ 7.2Hz, Ar-H), 7.44e7.52 (m, 3H, Ar-H), 7.90e7.96 (m,
3H, Ar-H), 8.86 (s, 1H, CH), 9.18 (t, 1H, J ¼ 6.0Hz, NH), 12.94 (brs, 1H,
OH); Anal. calcd. for C25H18FNO6: C, 67.11; H, 4.06; N, 3.13; found: C
67.22, H 4.00, N 3.20.
4.5.14. 4-((7-(4-ﬂuorophenoxy)-2-oxo-2H-chromene-3-
carboxamido)methyl)benzoic acid (6n)
Yellow solid; yield: 92%; mp: 266e268 C; Rf ¼ 0.43 (petroleum
ether: ethyl acetate ¼ 3:1); IR (KBr): nmax (cm1) 3338 (NH), 1704,
Fig. 12. A diagrammatic represention of interactions between ligand 8a and HDAC1 at the active site after 70ns molecular dynamic simulation. The green dotted lines represent
hydrogen bond interaction and red arcs with radiating spokes represents the amino acids showing hydrophobic interaction with protein. Carbon, nitrogen and oxygen atoms have
been shown in black, blue and red, respectively. The violet lines represent the ligand bond. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred
to the web version of this article.)
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J ¼ 6.0 Hz,CH2), 5.25 (s, 2H, OCH2), 7.12 (dd, 1H, J1 ¼ 8.5Hz,
J2 ¼ 2.1Hz, Ar-H), 7.21e7.29 (m, 3H, Ar-H), 7.44 (d, 2H, J ¼ 8.1Hz, Ar-
H), 7.53e7.60 (m, 2H, Ar-H), 7.90e7.94 (m, 3H, Ar-H), 8.86 (s, 1H,
CH), 9.18 (t, 1H, J ¼ 6.0Hz, NH); 13C NMR (75 MHz, DMSO-d6)
d 42.97, 69.94, 101.64, 112.79, 114.61, 115.48, 115.74, 116.02, 127.77,
129.89, 130.81, 131.79, 132.11, 132.66, 144.73, 148.43, 156.56, 161.21,
162.15, 163.78, 167.66; Anal. calcd. for C25H18FNO6: C, 67.11; H, 4.06;
N, 3.13; found: C 67.04, H 3.97, N 3.23.
4.5.15. 4-((7-(2-chlorophenoxy)-2-oxo-2H-chromene-3-
carboxamido) methyl) benzoic acid (6o)
Yellow solid; yield: 75%; m: 262e264 C; Rf ¼ 0.33 (petroleum
ether: ethyl acetate ¼ 3:1); IR (KBr): nmax (cm1) 3342 (NH), 1705,
1659 and 1616 (CO); 1H NMR (300 MHz, DMSO-d6) d 4.62 (d, 2H,
J ¼ 6.0Hz, CH2), 5.37 (s, 2H, OCH2), 7.20 (dd, 1H, J1 ¼ 8.7Hz,
J2¼ 2.4Hz, Ar-H), 7.33 (d, 1H, J¼ 2.4Hz, Ar-H), 7.44e7.53 (m, 4H, Ar-
H), 7.61 (m, 1H, Ar-H), 7.71 (m, 1H, Ar-H), 7.95-7-8.02 (m, 3H, Ar-H),
8.92 (s, 1H, CH), 9.24 (t, 1H, J ¼ 6.0Hz, NH), 12.95 (s, 1H, OH); 13C
NMR (75 MHz, DMSO-d6) d 42.98, 68.42, 101.63, 112.97, 114.44,115.63, 127.80, 127.98, 129.74, 129.90, 130.03, 130.90, 131.30, 132.19,
133.59, 133.73, 144.84, 148.42, 156.57, 161.20, 162.14, 163.70, 167.55;
Anal. calcd. for C25H18ClNO6: C, 64.73; H, 3.91; N, 3.02; found: C
64.67, H 4.01, N 3.09.4.5.16. 4-((7-(4-chlorophenoxy)-2-oxo-2H-chromene-3-
carboxamido) methyl) benzoic acid (6p)
Yellow solid; yield: 80%; mp: 270e272 C; Rf ¼ 0.36 (petroleum
ether: ethyl acetate ¼ 3:1)
IR (KBr): nmax (cm1) 3340 (NH), 1703, 1656 and 1610 (CO); 1H
NMR (300MHz, DMSO-d6) d 4.61 (d, 2H, J¼ 6.0Hz, CH2), 5.28 (s, 2H,
OCH2), 7.12 (dd, 1H, J1 ¼ 8.7Hz, J2 ¼ 2.4Hz, Ar-H), 7.22 (d, 1H,
J ¼ 2.4Hz, Ar-H), 7.44e7.55 (m, 6H, Ar), 7.90e7.95 (m, 3H, Ar-H),
8.86 (s, 1H, CH), 9.18 (t, 1H, J ¼ 6.0Hz, NH), 12.95 (s, 1H, OH); 13C
NMR (75 MHz, DMSO-d6) d 42.97, 69.78, 101.70, 112.86, 114.53,
115.57, 127.78, 129.05, 129.83, 129.89, 130.33, 132.13, 133.30, 135.51,
144.79, 148.41, 156.55, 161.19, 162.22, 163.68, 167.63; Anal. calcd. for
C25H18ClNO6: C, 64.73; H, 3.91; N, 3.02; found: C 64.80, H 3.83, N
3.10.
Table 5
ADME and pharmacological parameter prediction for the coumarin compounds using QikProp.
Compound QPlogPo/wa QPPCacob QPlogBBc QPlogHERGd Percent Human
Oral Absorptione
QPlogKpf #metabg
8a 2.905 126.985 2.002 7.5 81.608 2.88 5
8b 2.998 123.45 2.136 7.405 81.936 3 6
8c 3.438 127.065 2.296 7.704 84.731 2.881 6
8d 3.459 127.274 1.865 7.42 84.869 3.046 5
8e 3.003 127.281 2.095 7.317 82.202 2.987 6
8f 3.423 127.86 2.235 7.518 84.692 2.903 6
8g 3.809 127.632 2.396 7.797 86.939 2.791 6
8h 4.741 127.213 2.467 8.909 79.415 2.097 7
8i 4.928 127.019 2.424 8.577 80.499 2.265 8
8j 5.035 127.492 2.501 8.702 68.194 2.309 8
8k 5.047 127.083 2.522 8.764 68.241 2.299 8
8l 4.875 127.592 2.384 8.757 80.224 2.19 7
8m 4.953 127.668 2.362 8.742 80.681 2.234 7
8n 4.94 128.263 2.341 8.679 80.642 2.245 7
8o 5.069 124.962 2.337 8.696 68.235 2.245 7
8p 5.225 128.14 2.325 8.764 69.343 2.263 7
8q 5.29 127.97 2.317 8.765 69.716 2.271 7
8r 4.831 127.832 2.553 8.688 79.976 2.209 8
8s 5.489 124.634 2.222 8.577 70.676 2.38 7
8t 5.553 124.588 2.202 8.557 71.047 2.418 7
8u 5.627 128.523 2.182 8.563 71.725 2.414 7
Entinostat 2.388 144.236 1.957 7.014 79.569 2.944 8
a Predicted octanol/water partition coefﬁcient (acceptable range: 2.0e6.5).
b Predicted Caco-2 cell permeability in nm/s (acceptable range: <25 is poor, >500 is great).
c Predicted brain/blood partition coefﬁcient (Concern value is 3.0 to 1.2).
d Predicted IC50 value for blockage of HERG Kþ channels (concern below 5).
e Predicted human oral absorption on 0e100% scale (acceptable range: <25% is poor, >80% is high).
f Predicted skin permeability, log Kp (acceptable range: 8.0 to 1.0).
g Number of likely metabolic reactions (acceptable range: 1e8).
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carboxamido) methyl) benzoic acid (6q)
Light brown solid; yield: 87%; mp: 258e260 C; Rf ¼ 0.35 (pe-
troleum ether: ethyl acetate ¼ 3:1)
IR (KBr): nmax (cm1) 3346 (NH), 1705, 1652 and 1611 (CO); 1H
NMR (300 MHz, DMSO-d6) d 4.61 (t, 2H, J ¼ 6.0Hz, CH2), 5.26 (s, 2H,
OCH2), 7.07e7.20 (m, 2H, Ar-H), 7.20 (d, 1H, J¼ 2.1Hz, Ar-H), 7.44 (d,
2H, J ¼ 6.9Hz, Ar-H), 7.61 (m, 3H, Ar-H), 7.91 (m, 3H, Ar-H), 8.85 (s,
1H, CH), 9.18 (t, 1H, J ¼ 6.0Hz, NH), 13.00 (s, 1H, OH); 13C NMR
(75 MHz, DMSO-d6) d 42.98, 69.78, 101.65, 112.86, 114.52, 115.55,
121.85, 127.78, 129.83, 129.89, 130.58, 131.97, 132.10, 135.93, 144.79,
148.41, 156.53, 161.19, 162.21, 163.66, 167.63; Anal. calcd. for
C25H18BrNO6: C, 59.07; H, 3.57; N, 2.76; found: C 59.00, H 3.65, N
2.82.4.5.18. 4-((7-(4-methoxyphenoxy)-2-oxo-2H-chromene-3-
carboxamido)methyl)benzoic acid (6r)
Yellow solid; Yield: 82%; mp: 220e222 C; Rf ¼ 0.49 (petroleum
ether: ethyl acetate ¼ 3:1); IR (KBr): nmax (cm1) 3342 (NH), 1701,
1659 and 1601 (CO); 1H NMR (300 MHz, DMSO-d6) d 3.77 (s, 3H,
CH3), 4.62 (d, 2H, J ¼ 6.0Hz, CH2), 5.19 (s, 2H, CH2), 6.97 (d, 2H,
J ¼ 8.4Hz, Ar-H), 7.10 (dd, 1H, J1 ¼ 8.7Hz, J2 ¼ 2.4Hz, Ar-H), 7.21 (d,
1H, J ¼ 2.1Hz, Ar-H), 7.42e7.47 (m, 4H, Ar-H), 7.90 (m, 3H, Ar-H),
8.86 (s, 1H, CH), 9.17 (t, 3H, J ¼ 6.0Hz, NH), 12.92 (S, 1H, OH); 13C
NMR (75MHz, DMSO-d6) d 42.97, 55.60, 70.51,101.61,112.67,114.40,
114.68, 115.34, 127.78, 128.27, 129.82, 129.90, 130.41, 132.06, 144.82,
148.47, 156.60, 159.75,161.25,162.24, 164.00, 167.63; Anal. calcd. for
C26H21NO7: C, 67.97; H, 4.61; N, 3.05; found: C 67.90, H 4.70, N 3.13.4.5.19. 4-((7-(2, 3-dichlorophenoxy)-2-oxo-2H-chromene-3-
carboxamido) methyl) benzoic acid (6s)
Pale yellow solid; yield: 85%; mp: 252e254 C; Rf ¼ 0.37 (pe-
troleum ether: ethyl acetate ¼ 3:1); IR (KBr): nmax (cm1) 3358
(NH), 1704, 1654 and 1611 (CO); 1H NMR (300 MHz, DMSO-d6)d 4.62 (t, 2H, J ¼ 6.0 Hz,CH2), 5.37 (s, 2H, OCH2), 7.10e7.21 (m, 3H,
Ar-H), 7.29 (d, 1H, J¼ 2.1Hz, Ar-H), 7.45 (d, 2H, J¼ 7.8Hz, Ar-H), 7.70
(m, 2H, Ar-H), 7.91 (m, 2H, Ar-H), 8.87 (s, 1H, CH), 9.19 (t, 1H,
J ¼ 6.0Hz, NH), 12.83 (brs, 1H, OH); 13C NMR (75 MHz, DMSO-d6)
d 42.98, 68.65, 101.71, 113.09, 114.41, 115.76, 127.79, 128.96, 129.45,
129.84, 129.90, 131.09,131.42,132.58, 136.45, 144.79, 148.38, 156.54,
161.17, 162.20, 163.48, 167.63; Anal. calcd. for C25H17Cl2NO6: C,
60.26; H, 3.44; N, 2.81; found: C 60.34, H 3.37, N 2.88.4.5.20. 4-((7-(2, 4-dichlorophenoxy)-2-oxo-2H-chromene-3-
carboxamido) methyl) benzoic acid (6t)
White solid; yield: 85%; mp: 245e247 C; Rf ¼ 0.38 (petroleum
ether: ethyl acetate ¼ 3:1); IR (KBr): nmax (cm1) 3341 (NH), 1706,
1652 and 1600 (CO); 1H NMR (300 MHz, DMSO-d6) d 4.62 (t, 2H,
J ¼ 6.0 Hz,CH2), 5.32 (s, 2H, OCH2), 7.5 (dd, 1H, J ¼ 8.7Hz, J ¼ 2.1Hz,
Ar-H), 7.28 (d, 1H, J¼ 1.8Hz, Ar-H), 7.45 (d, 2H, J¼ 8.1Hz, Ar-H), 7.52
(dd, 1H, J ¼ 8.1Hz, J ¼ 1.8Hz, Ar-H), 7.68 (d, 1H, J ¼ 8.4Hz, Ar-H), 7.74
(d, 1H, J ¼ 2.1Hz, Ar-H), 7.86e7.97 (m, 3H, Ar-H), 8.87 (s, 1H, CH),
9.19 (t, 1H, J ¼ 6.0Hz, NH), 12.88 (brs, 1H, OH); 13C NMR (75 MHz,
DMSO-d6) d 42.98, 67.78, 101.70, 113.06, 114.43, 115.74, 127.80,
128.15, 129.58, 129.74, 129.90, 131.09, 132.21, 132.45, 132.99, 134.56,
144.84, 148.39, 156.54, 161.17, 162.22, 163.51, 167.55; Anal. calcd. for
C25H17Cl2NO6: C, 60.26; H, 3.44; N, 2.81; found: C 60.19, H 3.52, N
2.75.4.5.21. 4-((7-(3, 4-dichlorophenoxy)-2-oxo-2H-chromene-3-
carboxamido) methyl) benzoic acid (6u)
White solid; yield: 85%; mp: 249e251 C; Rf ¼ 0.53 (n-hexane:
ethyl acetate ¼ 3:1); IR (KBr): nmax (cm1) 3353 (NH), 1705, 1656
and 1617 (CO); 1H NMR (300 MHz, DMSO-d6) d(ppm) d 4.61 (d, 2H,
J ¼ 6.0Hz, CH2), 5.30 (s, 2H, OCH2), 7.14 (dd, 1H, J1 ¼ 8.7Hz,
J2 ¼ 2.4Hz, Ar-H), 7.23 (d, 1H, J¼ 2.1Hz, Ar-H), 7.44e7.52 (m, 3H, Ar-
H), 7.69 (d, 1H, J¼ 8.1Hz, Ar-H), 7.79 (d,1H, J¼ 1.8Hz, Ar-H), 7.93 (m,
3H, Ar-H), 8.86 (s, 1H, CH), 9.18 (t, 1H, J ¼ 6.0Hz, NH), 12.92 (s, 1H,
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114.56, 115.70, 127.78, 128.64, 129.89, 130.31, 131.27, 131.30,
131.68,132.17, 137.70, 144.79, 148.38, 156.52, 161.17, 162.20, 163.45,
167.63; Anal. calcd. for C25H17Cl2NO6: C, 60.26; H, 3.44; N, 2.81;
found: C 60.20, H 3.45, N 2.91.
4.6. General procedure for the synthesis of N-(4-((2-aminophenyl)
carbamoyl) benzyl)-2-oxo-2H-chromene-3-carboxamides (8a-u)
To a suspension of 4-((2-oxo-2H-chromene-3-carboxamido)
methyl) benzoic acids (6a-u) (5 mmol) in dry THF (10 mL) was
added CDI (19 mmol), and the mixture was stirred for 3 h at 60 C.
The clear solutionwas cooled to rt. To this solutionwere added 1, 2-
phenylenediamine (7, 25 mmol) and TFA (1.2 mL) and then stirred
for 16 h. The reaction mixture was evaporated to remove THF and
the crude product was stirred in a mixture of hexane and water
(2:5, v/v) for 1 h and ﬁltered and dried. The residue was triturated
in dichloromethane twice to afford pure compounds.
4.6.1. N-(4-((2-aminophenyl) carbamoyl) benzyl)-2-oxo-2H-
chromene-3-carboxamide (8a)
White solid; yield: 90%; mp: 207e209 C; Rf ¼ 0.76 (petroleum
ether: ethyl acetate ¼ 3:2); IR (KBr): nmax (cm1) 3404 and 3322
(NH and NH2), 1720, 1653 and 1609 (CO); 1H NMR (300 MHz,
DMSO-d6) d 4.64 (d, 2H, J ¼ 6.0 Hz, CH2), 4.90 (s, 2H, NH2, D2O
exchangable), 6.62 (t,1H, J¼ 6.6 Hz, Ar-H), 6.79 (d,1H, J¼ 7.5 Hz, Ar-
H), 6.93 (t, 1H, J ¼ 7.5 Hz, Ar-H), 7.18 (d, 1H, J ¼ 6.0 Hz, Ar-H),
7.48e7.55 (m, 4H, Ar-H), 7.75 (t, 1H, J ¼ 6.0 Hz, Ar-H), 7.98 (m,
2H, Ar-H), 8.90 (s, 1H, CH), 9.22 (t, 1H, J ¼ 6.0 Hz, NH, D2O
exchangable), 9.64 (s, 1H, NH, D2O exchangable); 13C NMR (75MHz,
DMSO-d6) d 43.03, 116.63, 116.79, 118.95, 119.58, 123.70, 125.63,
126.93,127.05,127.63,128.36,129.93,130.75,133.75,134.62,143.00,
148.05, 154.39, 160.78, 161.91, 165.53; LCMS(ESI, m/z): (Mþ1)þ
414.0, [2 M þ 1]þ 827.2; Anal. calcd. for C24H19N3O4: C, 69.72; H,
4.63; N, 10.16; found: C 69.78, H 4.69, N 10.06.
4.6.2. N-(4-((2-aminophenyl) carbamoyl) benzyl)-8-methoxy-2-
oxo-2H-chromene-3-carboxamide (8b)
White solid; yield: 80%; mp: 213e215 C; Rf ¼ 0.65 (petroleum
ether: ethyl acetate ¼ 3:2); IR (KBr): nmax (cm1) 3402 and 3342
(NH and NH2),1701,1659 and 1601 (CO); 1H NMR (300MHz, DMSO-
d6) d 3.95 (s, 3H, OCH3), 4.58 (d, 2H, J ¼ 6.0 Hz, CH2), 4.95 (s, 2H,
NH2),6.64 (t, 1H, J¼ 6.0 Hz, Ar-H), 6.79 (d, 1H, J¼ 6.6 Hz, Ar-H), 6.97
(t, 1H, J ¼ 6.6 Hz, Ar-H), 7.15 (d, 1H, J ¼ 6.6 Hz, Ar-H), 7.30e7.50 (m,
5H, Ar-H), 7.95 (d, 2H, J ¼ 6.6 Hz, Ar-H), 8.87 (s, 1H, CH), 9.23 (t, 2H,
J ¼ 6.0 Hz, NH), 9.66 (s, 1H, NH); 13C NMR (75 MHz, DMSO-d6)
d 43.04, 56.69, 116.59, 116.80, 119.51, 119.70, 121.66, 123.71, 125.58,
126.93, 127.04, 127.66, 128.36, 133.76, 142.99, 143.41, 143.72, 146.77,
148.27, 160.49, 161.88, 161.93, 165.59; LCMS(ESI, m/z): [Mþ1]þ
444.0, (2 M þ 1)þ 887.3; Anal. calcd. for C25H21N3O5: C, 67.71; H,
4.77; N, 9.48; found: C 67.82, H 4.82, N 9.56.
4.6.3. N-(4-((2-aminophenyl) carbamoyl) benzyl)-8-ethoxy-2-oxo-
2H-chromene-3-carboxamide (8c)
White solid; yield: 87%; mp: 218e220 C; Rf ¼ 0.46 (petroleum
ether: ethyl acetate ¼ 3:2); IR (KBr): nmax (cm1) 3400 and 3326
(NH and NH2), 1720, 1653 and 1613 (CO); 1H NMR (300 MHz,
DMSO-d6) d 1.43 (t, 3H, J ¼ 6.9 Hz, CH3), 4.23 (q, 2H, J ¼ 6.9 Hz,
OCH2), 4.63 (s, 2H, J ¼ 5.4 Hz, CH2), 4.92 (s, 2H, NH2), 6.61 (t, 1H,
J¼ 6.9 Hz, Ar-H), 6.78 (d, 1H, J¼ 6.9 Hz, Ar-H), 7.00 (t, 1H, J¼ 6.9 Hz,
Ar-H), 7.17 (d, 1H, J ¼ 7.2 Hz, Ar-H), 7.33e7.54 (m, 5H, Ar-H), 7.95 (d,
2H, J ¼ 8.1 Hz, Ar-H), 8.87 (s, 1H, CH), 9.24 (t, 1H, J ¼ 6.0 Hz, NH),
9.66 (s, 1H, NH); 13C NMR (75 MHz, DMSO-d6) d 15,04, 43.01, 65.00,
116.56, 116.74, 117.37, 119.60, 121.61, 123.65, 123.76, 125.58, 126.95,
127.15, 127.65, 128.36, 133.76, 143.00, 143.50, 143.76, 145.98, 148.35,160.57, 161.90, 165.61; LCMS(ESI, m/z): 458.0 [Mþ1]þ, 915.1
[2 M þ 1]þ; Anal. calcd. for C26H23N3O5: C, 68.41; H, 5.07; N, 9.19;
found: C 68.29, H 5.01, N 9.05.
4.6.4. N-(4-((2-aminophenyl)carbamoyl)benzyl)-7-methoxy-2-
oxo-2H-chromene-3- carboxamide (8d)
Yellow solid; yield: 92%; mp: 212e214 C; Rf ¼ 0.53 (petroleum
ether: ethyl acetate ¼ 3:2); IR (KBr): nmax (cm1) 3402 and 3342
(NH and NH2),1701,1659 and 1601 (CO); 1H NMR (300MHz, DMSO-
d6) d 3.91 (s, 3H, OCH3), 4.62 (d, 2H, J ¼ 5.4Hz, CH2), 4.94 (brs, 2H,
NH2), 6.61 (t, 1H, J ¼ 7.2Hz, Ar-H), 6.78 (d, 1H, J ¼ 7.8Hz, Ar-H), 7.00
(t, 1H, J ¼ 7.2Hz, Ar-H), 7.05 (m, 3H, Ar-H), 7.48 (d, 2H, J¼ 8.4Hz, Ar-
H), 7.95 (m, 3H, Ar-H), 8.87 (s, 1H, CH), 9.19 (t, 1H, J ¼ 5.4Hz, NH),
9.66 (s, 1H, NH); 13C NMR (75 MHz, DMSO-d6) d 42.85, 56.75,
100.78, 112.62, 114.14, 115.32, 116.59, 116.79, 123.68, 126.95, 127.07,
127.61, 128.36, 132.07, 133.70, 143.12, 143.42, 148.48, 156.70, 161.26,
162.19, 164.94, 165.53; LCMS(ESI, m/z): 444.0 [Mþ1]þ, 887.3
[2 M þ 1]þ; Anal. calcd. for C25H21N3O5: C, 67.71; H, 4.77; N, 9.48;
found: C 67.86, H 4.63, N 9.59.
4.6.5. N-(4-((2-aminophenyl) carbamoyl) benzyl)-7-ethoxy-2-oxo-
2H-chromene-3-carboxamide (8e)
Yellow solid; yield: 87%; mp: 224e226 C; Rf ¼ 0.53 (petroleum
ether: ethyl acetate ¼ 3:2); IR (KBr): nmax (cm1) 3409 and 3330
(NH and NH2),1714,1653 and 1614 (CO); 1H NMR (300MHz, DMSO-
d6) d 1.38 (t, 3H, J ¼ 6.3Hz, CH3), 4.18 (q, 2H, J ¼ 6.6Hz, OCH2), 4.62
(d, 2H, J ¼ 4.8Hz, 2CH2), 4.99 (brs, 2H, NH2), 6.61 (t, 1H, J ¼ 6.6Hz,
Ar-H), 6.93e6.7.19 (m, 5H, Ar-H), 7.47 (d, 2H, J ¼ 7.8Hz, Ar-H), 7.94
(m, 3H, Ar-H), 8.87 (s,1H, CH), 9.18 (t, 1H, J¼ 7.8 Hz, NH), 9.66 (s, 1H,
NH); 13C NMR (75 MHz, DMSO-d6) d 14.81, 42.97, 64.90, 101.11,
112.51, 114.38, 115.21, 116.56, 116.74, 123.66, 126.94, 127.08, 127.61,
128.36, 132.08, 133.71, 143.13, 143.54,148.49, 156.70, 161.32, 162.19,
164.21, 165.60; LCMS(ESI, m/z): 458.1 [Mþ1]þ, 915.1 [2 M þ 1]þ;
Anal. calcd. for C26H23N3O5: C, 68.26; H, 5.07; N, 9.19; found: C
68.10, H 5.17, N 9.31.
4.6.6. N-(4-((2-aminophenyl) carbamoyl) benzyl)-2-oxo-7-
propoxy-2H-chromene-3-carboxamide (8f)
Yellow solid; yield: 89%; mp: 219e221 C; Rf ¼ 0.54 (petroleum
ether: ethyl acetate ¼ 3:2); IR (KBr): nmax (cm1) 3403 and 3335
(NH and NH2), 1706, 1652 and 1618 (CO); 1H NMR (300 MHz,
DMSO-d6) d 1.00 (t, 3H, J ¼ 7.2Hz, CH3), 1.79 (se, 2H, J ¼ 6.9Hz, CH2),
4.10 (t, 2H, J¼ 6.6Hz, OCH2), 4.62 (d, 2H, J¼ 5.7Hz, CH2), 4.89 (s, 2H,
NH2), 6.61 (t, 1H, J ¼ 7.8Hz, Ar-H), 6.78 (d, 1H, J ¼ 6.9Hz, Ar-H), 6.96
(d, 2H, J ¼ 8.7Hz, Ar-H), 7.12 (d, 1H, J ¼ 7.5Hz, Ar-H), 7.18 (d, 1H,
J ¼ 7.5Hz, Ar-H), 7.46 (d, 2H, J ¼ 8.1Hz, Ar-H), 7.90e7.97 (m, 3H, Ar-
H), 8.87 (s, 1H, CH), 9.18 (t, 1H, J ¼ 6.0Hz, NH), 9.66 (s, 1H, NH); 13C
NMR (75 MHz, DMSO-d6) d 10.75, 22.24, 42.85, 70.57, 101.17, 112.52,
114.42, 115.21, 116.58, 116.78, 123.69, 126.93, 127.05, 127.61, 128.36,
132.09, 133.72, 143.11, 148.49, 156.71,161.30, 162.12, 164.39, 165.58;
LCMS(ESI, m/z): 472.0 [Mþ1]þ, 943.3 [2 M þ 1]; Anal. calcd. for
C27H25N3O5: C, 68.78; H, 5.34; N, 8.91; found: C 68.89, H 5.22, N
8.80.
4.6.7. N-(4-((2-aminophenyl) carbamoyl) benzyl)-6-bromo-2-oxo-
2H-chromene-3-carboxamide (8g)
White solid; yield: 90%; mp: 283e285 C; Rf ¼ 0.53 (n-hexane:
ethyl acetate ¼ 3:2); IR (KBr): nmax (cm1) 3402 and 3343 (NH and
NH2), 1714, 1653 and 1611 (CO); 1H NMR (300 MHz, DMSO-d6)
d 4.62 (d, 2H, J ¼ 5.7Hz, CH2), 5.07 (brs, 2H, NH2), 6.61 (t, 1H,
J ¼ 7.2Hz, Ar-H), 6.79 (d, 1H, J ¼ 7.5Hz, Ar-H), 6.98 (t, 1H, J ¼ 7.2Hz,
Ar-H), 7.17 (d, 1H, J ¼ 7.8Hz, Ar-H), 7.47e7.52 (m, 3H, Ar-H),
7.88e7.98 (m, 3H, Ar-H), 8.26 (d, 1H, J ¼ 2.1Hz, Ar-H), 8.85 (s, 1H,
CH), 9.21 (t, 1H, J ¼ 6.0Hz, NH), 9.66 (s, 1H, NH); 13C NMR (75 MHz,
DMSO-d6) d 42.94, 116.62, 116.84, 117.12, 118.91, 123.70, 126.96,
T. Abdizadeh et al. / European Journal of Medicinal Chemistry 132 (2017) 42e6258127.07, 127.62, 128.35, 129.92, 130.10, 132.57, 133.72, 136.74, 142.92,
143.38, 146.70, 155.63, 160.26,161.54,165.54; LCMS(ESI,m/z): 493.7
[Mþ1]þ; Anal. calcd. for C24H18BrN3O4: C, 58.55; H, 3.69; N, 8.54;
found: C 58.67, H 3.80, N 8.61.
4.6.8. N-(4-((2-aminophenyl) carbamoyl) benzyl)-7-(benzyloxy)-2-
oxo-2H-chromene-3-carboxamide (8h)
White solid; yield: 80%; mp: 212e214 C; Rf ¼ 0.58 (petroleum
ether: ethyl acetate ¼ 3:2); IR (KBr): nmax (cm1) 3407 and 3332
(NH and NH2), 1703, 1656 and 1612 (CO); 1H NMR (300 MHz,
DMSO-d6) d 4.63 (d, 2H, J ¼ 5.7Hz, CH2), 4.90 (brs, 2H, NH2), 5.28 (s,
2H, OCH2),6.61 (t,1H, J¼ 7.2Hz, Ar-H), 6.80 (d,1H, J¼ 7.2, Ar-H), 7.01
(t, 1H, J ¼ 7.2Hz, Ar-H), 7.12e7.22 (m, 3H, Ar-H), 7.39e7.51 (m, 7H,
Ar-H), 7.95 (m,3H, Ar-H), 8.87 (s, 1H, CH), 9.18 (t, 1H, J ¼ 6.0Hz, NH),
9.66 (s,1H, NH); 13C NMR (75MHz, DMSO-d6) d 42.98, 70.68,101.66,
112.78, 114.65, 115.50, 116.59, 116.77, 123.68, 123.79, 126.94, 127.06,
127.62, 128.50, 128.71, 129.04, 129.97, 132.11, 136.44, 143.12, 143.49,
148.40, 156.57, 161.26, 162.18, 163.90, 165.55; LCMS(ESI,m/z): 542.0
[Mþ23]þ, 1062.2 [2 M þ 23]þ, 1581.0 [3 M þ 23]þ; Anal. calcd. for
C31H25N3O5: C, 71.66; H, 4.85; N, 8.09; found: C, 71.49, H, 5.01, N,
7.92.
4.6.9. N-(4-((2-aminophenyl) carbamoyl) benzyl)-7-((2-
methylbenzyl) oxy)-2-oxo-2H-chromene-3-carboxamide (8i)
White solid; Yield: 86%; mp: 207e209 C; Rf ¼ 0.62 (petroleum
ether: ethyl acetate ¼ 3:2); IR (KBr): nmax (cm1) 3409 and 3335
(NH and NH2), 3052, 2926 (CH2) 1704, 1658 and 1616 (CO); 1H NMR
(300MHz, DMSO-d6) d 2.35 (s, 3H, CH3), 4.63 (d, 2H, J¼ 5.7Hz, CH2),
4.93 (brs, 2H, NH2), 5.27 (s, 2H, OCH2), 6.61 (t, 1H, J ¼ 6.9Hz, Ar-H),
6.87 (d, 1H, J ¼ 6.9Hz, Ar-H), 6.98 (t, 1H, J ¼ 6.9Hz, Ar-H) 7.13e7.21
(m, 2H, Ar-H), 7.23e7.29 (m, 4H, Ar-H 7.45e7.50 (m, 3H, Ar-H),
7.93e7.99 (m, 3H, Ar-H), 8.88 (s, 1H, CH), 9.19 (t, 1H, J ¼ 6.0Hz,
NH), 9.67 (s, 1H, NH); 13C NMR (75 MHz, DMSO-d6) d 18.96, 42.99,
69.46, 101.63, 112.81, 114.60, 115.47, 116.58, 172.73, 123.79, 126.58,
126.94, 127.15, 127.63, 128.37, 128.95, 129.32, 130.74, 132.12, 133.78,
134.38, 137.36, 143.11, 143.59, 148.43, 156.62, 161.28, 162.17, 164.03,
165.60; LCMS(ESI,m/z): 534.1 [Mþ1]þ; Anal. calcd. for C32H27N3O5:
C, 72.03; H, 5.10; N, 7.88; found: C, 72.15; H 5.28; N, 7.71.
4.6.10. N-(4-((2-aminophenyl) carbamoyl) benzyl)-7-((3-
methylbenzyl) oxy)-2-oxo-2H-chromene-3-carboxamide (8j)
White solid; Yield: 88%; mp: 213e215 C; Rf ¼ 0.52 (petroleum
ether: ethyl acetate ¼ 3:2); IR (KBr): nmax (cm1) 3402 and 3340
(NH and NH2), 1704, 1658 and 1602 (CO); 1H NMR (300 MHz,
DMSO-d6) d 2.34 (s, 3H, CH3), 4.62 (d, 2H, J ¼ 5.7Hz, CH2), 4.95 (brs,
2H, NH2), 5.23 (s, 1H, OCH2), 6.61 (t, 1H, J ¼ 7.5Hz, Ar), 6.80 (d, 1H,
J ¼ 7.5Hz, Ar-H), 6.96 (t, 1H, J ¼ 8.1Hz, Ar-H), 7.00e7.21 (m, 4H, Ar-
H), 7.29e7.34 (m, 3H, Ar-H), 7.47 (d, 2H, J ¼ 8.1Hz, Ar-H), 7.95 (m,
3H, Ar-H), 8.87 (s, 1H, CH), 9.18 (t, 1H, J ¼ 5.7Hz, NH), 9.66 (s, 1H,
NH); 13C NMR (75 MHz, DMSO-d6) d 21.44, 42.98, 70.72, 101.61,
112.75, 114.64, 115.45, 116.60, 116.76, 123.78, 125.59, 126.97, 127.16,
127.62, 128.36, 128.95, 129.34, 130.10, 132.10, 133.74, 136.33, 138.26,
143.11, 143.57, 148.41, 156.57, 161.27, 162.19, 163.93, 165.63;
LCMS(ESI): 533.9 [Mþ1]þ; Anal. calcd. for C32H27N3O5: C, 72.03; H,
5.10; N, 7.88; found: C, 71.89; H, 5.25; N, 8.01.
4.6.11. N-(4-((2-aminophenyl) carbamoyl) benzyl)-7-((4-
methylbenzyl) oxy)-2-oxo-2H-chromene-3-carboxamide (8k)
White solid; Yield: 90%, mp: 221e223 C; Rf ¼ 0.53 (petroleum
ether: ethyl acetate ¼ 3:2); IR (KBr): nmax (cm1) 3404 and 3345
(NH and NH2), 3030, 2921 (CH2), 1707, 1655 and 1608 (CO), 1565,
1525, 1450, 1224, 1147, 822, 741; 1H NMR (300 MHz, DMSO-d6)
d 2.32 (s, 3H, CH3), 4.62 (d, 2H, J ¼ 6.0Hz, CH2), 4.90 (brs, 2H, NH2),
5.22 (s, 2H, CH2), 6.61 (t, 1H, J ¼ 7.2Hz, Ar-H), 6.80 (d, 1H, J ¼ 6.9Hz,
Ar-H), 6.98 (t, 1H, J ¼ 7.2Hz, Ar-H) 7.12e7.24 (m, 5H, Ar-H), 7.37 (d,2H, J¼ 7.8Hz, Ar-H), 7.46 (d, 2H, J¼ 8.1Hz, Ar-H), 7.94 (m, 3H, Ar-H),
8.86 (s, 1H, CH), 9.18 (t, 1H, J¼ 6.0Hz, NH), 9.66 (s, 1H, NH); 13C NMR
(400 MHz, DMSO-d6) d 21.26, 42.97, 70.59, 101.63, 112.70, 114.69,
115.40, 116.60, 116.77, 123.76, 126.98, 127.16, 127.62, 128.36, 128.60,
129.68, 132.08, 133.37, 133.73, 138.05, 143.11, 143.57, 148.42, 156.56,
161.27, 162.20, 163.93, 165.94; LCMS(ESI, m/z): 556.1 [Mþ23]þ,
1089.2 [2Mþ 23]þ; Anal. calcd. for C32H27N3O5: C, 72.03; H, 5.10; N,
7.88; found: C, 72.23; H, 4.91; N, 8.09.
4.6.12. N-(4-((2-aminophenyl) carbamoyl) benzyl)-7-((2-
ﬂuorobenzyl) oxy)-2-oxo-2H-chromene-3-carboxamide (8l)
White solid; yield: 86%; mp: 215e217 C; Rf ¼ 0.67 (petroleum
ether: ethyl acetate ¼ 3:2); IR (KBr): nmax (cm1) 3401 and 3354
(NH and NH2),1718,1654 and 1616 (CO); 1H NMR (300MHz, DMSO-
d6) d 4.63 (d, 2H, J2 ¼ 5.7Hz, CH2), 5.04 (brs, 2H, NH2), 5.32 (s, 2H,
OCH2), 6.61 (t, 1H, J2 ¼ 7.2Hz, Ar-H), 6.78 (d, 1H, J2 ¼ 8.1Hz, Ar-H),
6.98 (t, 1H, J2 ¼ 6.9Hz, Ar-H), 7.13e7.20 (m, 2H, Ar-H), 7.25e7.33
(m, 3H, Ar-H), 7.47 (m, 3H, Ar-H), 7.62 (t, 1H, J2 ¼ 7.5Hz, Ar-H),
7.94e8.00 (m, 3H, Ar-H), 8.88 (s, 1H, CH), 9.18 (t, 1H, J2 ¼ 6.0Hz,
Ar), 9.65 (s, 1H, NH); 13C NMR (75 MHz, DMSO-d6) d 43.00, 65.13,
101.57, 112.91, 114.47, 115.61, 115.86, 116.64, 116.82, 123.32, 123.80,
125.15, 1126.99, 127.63, 128.37, 130.09, 131.48, 131.57, 131.62, 132.15,
143.10, 143.55, 148.37, 156.55, 159.40, 161.25, 162.19, 163.68, 165.68;
LCMS(ESI, m/z): 538.0 [Mþ1]þ; Anal. calcd. for C31H24FN3O5: C,
69.27; H, 4.50; N, 7.82; found: C, 69.15; H, 4.37; N, 7.70.
4.6.13. N-(4-((2-aminophenyl) carbamoyl) benzyl)-7-((3-
ﬂuorobenzyl) oxy)-2-oxo-2H-chromene-3-carboxamide (8m)
White solid; yield: 88%; mp: 208e210 C; Rf ¼ 0.65 (petroleum
ether: ethyl acetate ¼ 3:2)
IR (KBr): nmax (cm1) 3409 and 3340 (NH and NH2), 1704, 1658
and1602 (CO); 1H NMR (300 MHz, DMSO-d6) d 4.62 (d, 2H,
J2 ¼ 5.7Hz, CH2), 4.93 (brs, 2H, NH2), 5.31 (s, 2H, OCH2), 6.61 (t, 1H,
J ¼ 7.5Hz, Ar-H), 6.78 (d, 1H, J ¼ 7.8Hz, Ar-H), 7.00 (t, 1H, J2 ¼ 8.1Hz,
Ar-H), 7.13e7.24 (m, 4H, Ar-H), 7.33 (d, 2H, J ¼ 8.1Hz, Ar-H),
7.44e7.52 (m, 3H, Ar-H), 7.93e7.98 (m, 3H, Ar-H), 8.88 (s, 1H, CH),
9.19 (t, 1H, J2 ¼ 6.0Hz, Ar), 9.66 (s, 1H, NH); 13C NMR (75 MHz,
DMSO-d6) d 43.00, 69.74, 101.69, 112.90, 114.57, 114.88, 115.59,
116.60, 116.75, 123.80, 124.32, 126.96, 127.16, 127.62, 128.37, 130.12,
131.15, 132.13, 133.76, 139.28, 143.10, 143.59, 148.36, 156.52, 161.24,
162.15, 163.62, 164.28, 165.62; LCMS(ESI,m/z): 538.0 [Mþ1]þ; Anal.
calcd. for C31H24FN3O5: C, 69.27; H, 4.50; N, 7.82; found: C, 69.37; H,
4.49; N, 7.72.
4.6.14. N-(4-((2-aminophenyl) carbamoyl) benzyl)-7-((4-
ﬂuorobenzyl) oxy)-2-oxo-2H-chromene-3-carboxamide (8n)
White solid; yield: 86%; mp: 212e214 C; Rf ¼ 0.67 (petroleum
ether: ethyl acetate ¼ 3:2); IR (KBr): nmax (cm1) 3403 and 3346
(NH and NH2), 1707, 1656 and 1608 (CO); 1H NMR (300 MHz,
DMSO-d6) d 4.62 (d, 2H, J2¼ 5.7Hz, CH2), 4.92 (brs, 2H, NH2), 5.26 (s,
2H, OCH2), 6.62 (t, 1H, J2 ¼ 7.2Hz, Ar-H), 6.80 (d, 1H, J2 ¼ 6.9Hz, Ar-
H), 6.96 (t, 1H, J2¼ 6.9Hz, Ar-H), 7.11e7.30 (m, 5H, Ar-H), 7.49 (d, 2H,
J2 ¼ 8.1Hz, Ar-H), 7.54e7.60 (mt, 2H, Ar-H), 7.95 (m, 3H, Ar-H), 8.87
(s, 1H, CH), 9.18 (t, 1H, J2 ¼ 6.0Hz, Ar), 9.67 (s, 1H, NH); 13C NMR
(75 MHz, DMSO-d6) d 42.99, 69.94, 101.66, 112.82, 114.61, 115.54,
116.06, 116.60, 116.79, 123.81, 126.94, 127.12, 127.62, 128.36, 129.98,
130.12, 130.81, 132.11, 132.67, 133.73, 136.37, 143.11, 143.44, 148.39,
156.56, 161.25, 162.17, 163.78, 165.63; LCMS(ESI; m/z): 561.0
[Mþ23]þ, 1097.1 [2 M þ 23]þ, 1635.5 [3 M þ 23]þ; Anal. calcd. for
C31H24FN3O5: C, 69.27; H, 4.50; N, 7.82; found: C, 69.39; H, 4.39; N,
7.70.
4.6.15. N-(4-((2-aminophenyl) carbamoyl) benzyl)-7-((2-
chlorobenzyl)oxy)-2-oxo-2H-chromene-3-carboxamide (8o)
Yellow solid; yield: 87%; mp: 223e225 C; Rf ¼ 0.56 (petroleum
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(NH and NH2),1710,1654 and 1615 (CO); 1H NMR (300MHz, DMSO-
d6) d 4.62 (d, 2H, J¼ 6.0, CH2), 4.95 (brs, 2H, NH2), 5.28 (s, 2H, OCH2),
6.61 (t, 1H, J ¼ 7.2, Ar-H), 6.80 (d, 1H, J ¼ 7.2, Ar-H), 6.95 (t, 1H,
J ¼ 8.4, Ar-H), 7.01 (d, 1H, J ¼ 8.1, Ar-H), 7.11e7.22 (m, 3H, Ar-H),
7.49e7.55 (m, 5H, Ar-H), 7.95 (m, 3H, Ar-H), 8.87 (s, 1H, CH), 9.18
(t, 1H, J¼ 6.0Hz, NH), 9.66 (s, 1H, NH); 13C NMR (75MHz, DMSO-d6)
d 42.98, 68.43, 101.63, 112.98, 114.46, 115.67, 116.59, 116.77, 123.77,
126.97, 127.15, 127.63, 127.99, 128.37, 130.04, 130.10, 13.92, 131.30,
132.20,133.20,133.72,143.12,143.55,148.38,156.57,161.24,162.118,
163.70, 165.57; LCMS(ESI,m/z): 576.2 [Mþ23]þ, 1129.1 [2 M þ 23]þ,
1681.5 [3 M þ 23]þ; Anal. calcd. for C31H24ClN3O5: C, 67.21; H, 4.37;
N, 7.58; found: C, 67.09; H, 4.44; N, 7.49.4.6.16. N-(4-((2-aminophenyl) carbamoyl) benzyl)-7-((4-
chlorobenzyl) oxy)-2-oxo-2H-chromene-3-carboxamide (8p)
Yellow solid; yield: 87%; mp: 220e222 C; Rf ¼ 0.66 (petroleum
ether: ethyl acetate ¼ 3:2); IR (KBr): nmax (cm1) 3401 and 3344
(NH and NH2),1704,1658 and 1611 (CO); 1H NMR (300MHz, DMSO-
d6) d 4.62 (d, 2H, J¼ 6.0, CH2), 4.95 (brs, 2H, NH2), 5.28 (s, 2H, OCH2),
6.61 (t, 1H, J ¼ 7.2, Ar-H), 6.80 (d, 1H, J ¼ 7.2, Ar-H), 6.95 (t, 1H,
J ¼ 8.4, Ar-H), 7.01 (d, 1H, J ¼ 8.1, Ar-H), 7.11e7.22 (m, 3H, Ar-H),
7.49e7.55 (m, 5H, Ar-H), 7.95 (m, 3H, Ar-H), 8.87 (s, 1H, CH), 9.18
(t, 1H, J¼ 6.0Hz, NH), 9.66 (s, 1H, NH); 13C NMR (75MHz, DMSO-d6)
d 43.00, 69.77, 101.66, 112.86, 114.58, 115.53, 116.62, 116.77, 123.81,
126.96, 127.17, 127.62, 128.38, 129.04, 130.12, 132.11, 133.31, 133.76,
135.47, 143.10, 143.57, 148.37, 156.52, 161.24, 162.15, 163.66, 165.63;
LCMS(ESI, m/z): 554.1 [Mþ1]þ; Anal. calcd. for C31H24ClN3O5: C,
67.21; H, 4.37; N, 7.58; found: C, 67.10; H, 4.49; N, 7.43.4.6.17. N-(4-((2-aminophenyl) carbamoyl) benzyl)-7-((4-
bromobenzyl) oxy)-2-oxo-2H-chromene-3-carboxamide (8q)
White solid; yield: 90%; mp: 200e202 C; Rf ¼ 0.58 (petroleum
ether: ethyl acetate ¼ 3:2); IR (KBr): nmax (cm1) 3400 and 3321
(NH and NH2), 1690, 1653 and 1616 (CO); 1H NMR (300 MHz,
DMSO-d6) d 4.62 (d, 3H, J ¼ 6.0Hz, CH2), 4.93 (brs, 2H, NH2), 5.27 (s,
2H, OCH2), 6.63 (t, 1H, J ¼ 7.2Hz, Ar-H), 6.82 (d, 1H, J ¼ 7.8Hz, Ar-H),
6.95 (t,1H, J¼ 7.8Hz, Ar-H), 7.10e7.20 (m, 3H, Ar-H), 7.48 (m, 3H, Ar-
H), 7.61e7.65 (m, 3H, Ar-H), 7.92e7.99 (m, 3H, Ar-H), 8.87 (s, 1H,
CH), 9.18 (t, 1H, J ¼ 6.0Hz, NH), 9.66 (s, 1H, NH); 13C NMR (75 MHz,
DMSO-d6) d 42.99, 69.81, 101.68, 112.87, 114.59, 115.55, 116.60,
116.75, 121.82, 123.80, 126.95, 127.15, 127.62, 128.37, 129.37, 130.57,
132.11, 133.77, 135.90,143.09, 148.37, 156.52, 161.23, 162.14, 163.65,
165.62; LCMS(ESI, m/z): 597.9 [M]þ; Anal. calcd. for C31H24BrN3O5:
C, 62.22; H, 4.04; N, 7.02; found: C, 62.31; H, 4.12; N, 7.11.4.6.18. N-(4-((2-aminophenyl) carbamoyl) benzyl)-7-((4-
methoxybenzyl)oxy)-2-oxo-2H-chromene-3-carboxamide (8r)
Pale brown solid; Yield: 90%; mp: 202e204 C; Rf ¼ 0.64 (pe-
troleum ether: ethyl acetate ¼ 3:2); IR (KBr): nmax (cm1) 3405 and
3344 (NH and NH2), 1709, 1653 and 1616 ( ); 1H NMR (300MHz,
DMSO-d6) d 3.77 (s, 3H, CH3), 4.63 (d, 2H, J ¼ 6.0Hz, CH2), 4.93 (brs,
2H, NH2), 5.19 (s, 1H, OCH2), 6.61 (t, 1H, J¼ 7.2Hz, Ar-H), 6.80 (d, 1H,
J ¼ 7.2Hz, Ar-H), 6.96e7.01 (m, 3H, Ar-H), 7.12 (dd, 1H, J 1 ¼ 8.7Hz,
J2 ¼ 2.1Hz, Ar-H), 7.16e7.22 (m, 2H, Ar-H), 7.42e7.49 (m, 4H, Ar-H),
7.91e7.98 (m, 3H, Ar-H), 8.87 (s, 1H, CH), 9.18 (t, 1H, J ¼ 6.0Hz, NH),
9.66 (s, 1H, NH); 13C NMR (75 MHz, DMSO-d6) d 42.98, 55.58, 70.51,
101.59, 112.65, 114.39, 114.69, 115.32, 116.62, 116.80, 123.78, 126.99,
127.16, 127.63, 128.24, 130.39, 132.05, 133.73, 143.11, 143.56, 148.43,
156.57, 159.74, 161.29, 162.21, 163.99, 165.66; LCMS(ESI,m/z): 550.0
(Mþ1)þ; Anal. calcd. for C32H27N3O6: C, 69.93; H, 4.95; N, 7.65;
found: C, 69.83; H, 5.06; N, 7.54.4.6.19. N-(4-((2-aminophenyl) carbamoyl) benzyl)-7-((2,3-
dichlorobenzyl)oxy)-2-oxo-2H-chromene-3-carboxamide (8s)
White solid; yield: 88%; mp: 221e223 C; Rf ¼ 0.63 (petroleum
ether: ethyl acetate ¼ 3:2); IR (KBr): nmax (cm1) 3409 and 3358
(NH and NH2), 1704, 1658 and 1611 (CO); 1H NMR (300 MHz,
DMSO-d6) d 4.62 (d, 2H, J2¼ 5.7Hz, CH2), 4.91 (brs, 2H, NH2), 5.39 (s,
2H, OCH2), 6.60 (t, 1H, J2 ¼ 7.5Hz, Ar-H), 6.80 (d, 1H, J2 ¼ 8.1Hz, Ar-
H), 7.00 (t, 1H, J2¼ 8.1Hz, Ar-H), 7.15e7.21 (m, 2H, Ar-H), 7.30 (d, 1H,
J2 ¼ 2.4Hz, Ar-H), 7.43e7.7.50 (m, 3H, Ar-H), 7.66 (d, 1H, J2 ¼ 7.8Hz,
Ar-H), 7.72 (d,1H, J2¼ 7.8Hz, Ar-H), 7.94e8.02 (m, 3H, Ar-H), 8.88 (s,
1H, CH), 9.18 (t, 1H, J2 ¼ 6.0Hz, Ar-H), 9.65 (s, 1H, NH); 13C NMR
(75 MHz, DMSO-d6) d 42.99, 68.69, 101.75, 113.11, 114.41, 115.82,
116.57, 116.72, 123.78, 126.97, 127.15, 127.62, 128.36, 128.97, 129.48,
131.11, 131.44, 132.23, 133.77, 136.45, 143.10, 143.59, 148.34, 156.53,
161.20, 162.14, 163.48, 165.60; LCMS(ESI, m/z): 588.2 [M]þ; Anal.
calcd. for C31H23Cl2N3O5: C, 63.27; H, 3.94; Cl, 12.05; N, 7.14; found:
C, 63.14; H, 3.84; N, 7.03.
4.6.20. N-(4-((2-aminophenyl) carbamoyl) benzyl)-7-((2,4-
dichlorobenzyl)oxy)-2-oxo-2H-chromene-3-carboxamide (8t)
White solid; yield: 88%; mp: 200e202 C; Rf ¼ 0.63 (petroleum
ether: ethyl acetate ¼ 3:2); IR (KBr): nmax (cm1) 3405 and 3352
(NH and NH2), 1705, 1656 and 1614 (CO); 1H NMR (300 MHz,
DMSO-d6) d 4.62 (d, 2H, J2¼ 5.7Hz, CH2), 4.90 (brs, 2H, NH2), 5.32 (s,
2H, OCH2), 6.61 (t, 1H, J2 ¼ 7.5Hz, Ar-H), 6.80 (d, 1H, J2 ¼ 7.5Hz, Ar-
H), 7.00 (t, 1H, J2 ¼ 7.2Hz, Ar-H), 7.15 (m, 2H, Ar-H), 7.29 (d, 1H,
J2 ¼ 1.8Hz, Ar-H), 7.46e7.55 (m, 3H, Ar-H), 7.75 (m, 2H, Ar-H), 7.98
(m, 3H, Ar-H), 8.88 (s, 1H, CH), 9.19 (t, 1H, J2¼ 5.7Hz, Ar), 9.66 (s, 1H,
NH); 13C NMR (75 MHz, DMSO-d6) d 42.98, 67.78, 101.70, 113.07,
114.43, 115.79, 116.58, 116.77, 123.69, 126.93, 127.05, 127.62, 128.15,
128.36, 129.58, 129.93, 132.21, 132.44, 132.98, 133.72, 134.55, 143.11,
143.45, 148.34, 156.53, 161.21, 162.06, 163.50, 165.56; LCMS(ESI, m/
z): 589.1 [Mþ1]þ; Anal. calcd. for C31H23Cl2N3O5: C, 63.27; H, 3.94;
N, 7.14; found: C, 63.15; H, 4.08; N, 7.25.
4.6.21. N-(4-((2-aminophenyl) carbamoyl) benzyl)-7-((3,4-
dichlorobenzyl)oxy)-2-oxo-2H-chromene-3-carboxamide (8u)
White solid; yield: 87%; mp: 206e207 C; Rf ¼ 0.55 (petroleum
ether: ethyl acetate ¼ 3:2); IR (KBr): nmax (cm1) 3402 and 3355
(NH and NH2),1701,1654 and 1615 (CO); 1H NMR (300MHz, DMSO-
d6) d 4.62 (d, 2H, J ¼ 5.7Hz, CH2), 4.90 (brs, 2H, NH2), 5.30 (s, 2H,
OCH2), 6.61 (t, 1H, J¼ 7.2Hz, Ar-H), 6.80 (d, 1H, J¼ 8.1Hz, Ar-H), 7.98
(t, 1H, J ¼ 8.1Hz, Ar-H), 7.13e7.23 (m, 3H, Ar-H), 7.70 (d, 1H,
J ¼ 8.1Hz, Ar-H), 7.80 (d, 1H, J ¼ 1.8Hz, Ar-H), 7.93e7.97 (m, 3H, Ar-
H), 8.87 (s, 1H, CH), 9.18 (t, 1H, J ¼ 6.0Hz, NH), 9.65 (s, 1H, NH); 13C
NMR (75 MHz, DMSO-d6) d 42.98, 69.00, 101.74, 113.006, 114.47,
115.74, 116.58, 116.77, 123.68, 123.78, 126.94, 127.06, 127.61, 128.35,
128.63, 130.30, 131.30, 131.69, 132.18, 133.72, 137.70, 143.11, 143.45,
148.34, 156.51, 161.21, 162.14, 163.44, 165.52; LCMS(ESI, m/z): 588.1
[M]þ, 589.0 [Mþ1]þ, 1176.3 [2 M]þ; Anal. calcd. for C31H23Cl2N3O5:
C, 63.27; H, 3.94; N, 7.14; found: C 63.40, H 4.06, N, 7.02.
4.7. Biological evaluation
4.7.1. Cell growth inhibition assay
The level of in vitro proliferative response of cancer cells and
normal cells were estimated using MTT dye assay. Cancer cells and
normal cells were maintained in RPMI 1640 (Gibco, USA) and in
DMEM medium (Caisson, USA), respectively. After counting the
number of cells with a hemocytometer by 0.04% Trypan Blue dye
exclusion technique, the cells were cultured in 96-well microplates
(1  104 cells/100 mL in each well) with RPMI 1640 or DMEM me-
dium which were incubated for 24 h at 37 C in 5% CO2 incubator.
Inhibitor solutions were prepared by serial dilution of a 5 mM
DMSO stock solution with culture medium. The ﬁnal amount of
T. Abdizadeh et al. / European Journal of Medicinal Chemistry 132 (2017) 42e6260DMSO per well was maintained at below 1% V/V. Then, the cells
were treated with the different concetrations of the test com-
pounds, positive control Entinostat and medium alone with or
without 1% DMSO as negative controls for 48 h at 37 Cwith 5% CO2.
Thereafter, 150 mL MTT solution diluted in culture medium (5 mg/
ml) was added to each well and incubation continued for 4 h. Then,
the supernatants were carefully removed and formazan pre-
cipitates were dissolved in 150 mL of DMSO. Plates were shaken
vigorously (300 rpm) for 5 min. Finally, the difference of absor-
bance at 570 nm and 630 nm was measured with Microplate
Spectrophotometer (BioTec, USA). Each assay was performed in
triplicate. The inhibition percentage of test compounds with con-
centrations (10e100 mM) was calculated as: DODwells treated with
compounds/DOD wells treated with medium alone  100. Then, IC50 values
were calculated by nonlinear regression analysis using GraphPad
prism (Version 6.0) software and expressed in mean ± SD.
4.7.2. Whole-cell HDAC inhibition assay
Brieﬂy, human cancer cell lines A2780 and HCT-116 were seeded
in 96-well tissue culture microplates (1.5  104 cells/90 mL culture
medium in each well). After 24 h, cells were incubated for 18 h with
increasing concentrations of test compounds. The reaction was
started by adding 10 mL of 3mMBoc-Lys (ε-Ac)-AMC (Bachem, Koln,
Germany) to each well at a ﬁnal concentration of 0.3 mM. The cells
were incubated with the Boc-Lys (ε-Ac)-AMC for 3 h under cell
culture conditions. After this incubation, 100 mL/well stop solution
(25 mM Tris-HCl (pH 8), 137 mMNaCl, 2.7 mM KCl, 1 mMMgCl2, 1%
NP40, 2.0 mg/mL trypsin, 10 mM vorinostat) was added and the
mixture was developed for 3 h under cell culture conditions.
Fluorescence intensity was measured at an excitation of 320 nm
and emission of 520 nm in a NOVOstar microplate reader (BMG
LabTech, Offenburg, Germany) [47].
4.7.3. In vitro HDAC1 inhibition ﬂuorescence assay
The HDAC1 inhibitory activity of the four potent compounds
was evaluated using commercially HDAC1 ﬂuorescent Activity
Assay Kit (Biomol, #AK511, USA) following the manufacturer
manual. Brieﬂy, HDAC1 enzyme, test compounds and substrate
were diluted with HDAC assay buffer (50 mM Tris-HCl, pH 8.0,
137mMNaCl, 2.7 mMKCl,1mMMgCl2,1 mg/mL BSA).15 mL diluted
HDAC1 enzyme was preincubated with 10 mL of different con-
cetrations of the test compounds (10e100 mM) in 96-well micro-
plates for 5 min at 30 C. To start the reaction, deacetylase
ﬂuorogenic substrate (25 mL) was added and the reaction mixture
incubated for 30 min at 30 C. Then, the reaction was stopped by
addition of 50 mL developer/TSA (trichostatin A). After 45 min in-
cubation, the ﬂuorescent intensity was measured by a microplate
reader at excitation and emission wavelengths of 350 and 460 nm,
respectively. The inhibition ratios were calculated from the ﬂuo-
rescence intensity readings of tested wells relative to those of
control wells [51]. IC50 values were calculated by nonlinear
regression analysis using GraphPad prism (Version 6.0) software
and expressed in mean ± SD.
4.8. Molecular docking
The molecular docking process performed using AutoDock4.2
(http://autodock.scripps.edu/) to predict the best possible biolog-
ical conformation of target compound in the active site of a
particular protein. The x-ray crystal structure of HDAC1 (PDB ID:
4BKX) with resolution 2.5 A

was downloaded from the Protein
Data Bank (PDB). Water molecules, co-crystallized ligand and all
ions except the catalytic zinc ionwere removed and polar hydrogen
atoms were added to the receptor, then the protein was saved with
pdbqt format using the graphical user interface Autodock tools(ADT, 1.5.6). The 2D structure of the target compounds was pre-
pared using Chem Draw Ultra 8.0 software (http://www.
cambridgesoft.com/) and converted to 3D format by Hyper
Chem7 (Hyper cube Inc, USA) using AM1 semi-empirical method,
and the pdbqt format of the target compounds was prepared using
ADT. The target compounds were docked into the active pocket of
HDAC1. A gridbox size of 70 70 70 points with 0.375 A spacing
between the grid points was used. Gridbox center was located at
center of co-crystallized ligand (x ¼ 47.557, y ¼ 16.078,
z ¼ 4.771). AutoGrid 4.2 was used to generate the grid map ﬁles
for the docking calculations. Then AutoDock4.2 was run. Lamarck-
ian Genetic Algorithm (GA) parameters were set to 100 GA runs
with a population size of 150; a maximum number of 2.5  105
energy evaluation and 2.7  104 generation were used. The other
parameters were set as default. The output DLG ﬁles were con-
verted to pdb format and Molecular Operating Environment (MOE)
(www.chemcomp.com) was employed to view the docking results.
The best docking pose of compound 8a was chosen for Molecular
dynamic (MD) simulation.4.9. Molecular dynamic simulation
Molecular Dynamic (MD) simulation studies were performed to
investigate the interaction between the protein and ligand in
atomic details at real physiological condition aqueous solution at
T ¼ 37 C, P ¼ 1atm. Calculations were performed using the
Nanoscale Molecular Dynamics NAMD 2.9 program (www.ks.uiuc.
edu/Research/namd) with CHARMM27 force ﬁeld. The visualiza-
tion package Visual Molecular Dynamics (VMD) (www.ks.uiuc.edu/
Research/vmd) was used to analyze results. The force ﬁeld pa-
rameters of the ligand 8a were prepared by SwissParam (http://
swissparam.chr). The structure of protein was checked for
missing atoms and bonds the whole systems were immersed in the
center of a TIPS water box with dimensions 6  6 6 nm, using the
VMD program and the systems were neutralized by adding sodium
and chloride ions and energy minimization with the steepest
descent method for 5000 steps. The Particle-Mesh Ewald (PME)
algorithm with a grid spacing of 1A

and periodic boundary con-
ditionswere applied. A cut-off 15 (Å) was applied to the short-range
Lennard-Jones interactions. Finally, the MD simulations were per-
formed with a time step of 2 fs for 70 ns (ns). The trajectory of the
system was stored at every 1ps and analyzed by VMD analyzer
Tools.
The system was complex and required signiﬁcant computa-
tional. We used resources at the National High-Performance
Computing Center Isfahan University of Technology (http://
nhpcc.iut.ac.ir). 32 Intel xenon processors (2.5-GHz) were
employed.4.10. Prediction of physicochemical and ADME properties
The physicochemical and ADME properties of the coumarin
compounds as drug candidate were predicted using Schr€odinger
module QikProp 0.8 (Schr€odinger, LLC, New York, 2015, USA). It is a
quick, accurate and easy method for prediction of absorption, dis-
tribution, metabolism, elimination and toxicity (ADMET)
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